

Access DB#

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Grace Hsu Examiner #: 8 Date: 8/28/00  
Art Unit: 1628 Phone Number 308-7005 Serial Number: PCT 90/020442  
Mail Box and Bldg/Room Location: 80-12 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Benzimidazole Derivatives & Combinational Libraries therefrom  
Inventors (please provide full names): ZANG, Hengyuan + Pei, Yezhong

Earliest Priority Filing Date: 9/21/99

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1-34

Please Search 09/401,004

09/401,004

Christina Chan

-1640

Rush

RECEIVED  
AUG 30 2000  
TECHNICAL SERVICES  
(CHIC)

## STAFF USE ONLY

Searcher: Jan  
Searcher Phone #: 4498  
Searcher Location: \_\_\_\_\_  
Date Searcher Picked Up: 8/30  
Date Completed: 8/31  
Searcher Prep & Review Time: \_\_\_\_\_  
Clerical Prep Time: 45  
Online Time: 585

## Type of Search

NA Sequence (#) \_\_\_\_\_  
AA Sequence (#) \_\_\_\_\_  
Structure (#) ☒ \_\_\_\_\_  
Bibliographic \_\_\_\_\_  
Litigation \_\_\_\_\_  
Fulltext \_\_\_\_\_  
Patent Family \_\_\_\_\_  
Other \_\_\_\_\_

## Vendors and cost where applicable

STN ☒ \_\_\_\_\_  
Dialog \_\_\_\_\_  
Questel/Orbit \_\_\_\_\_  
Dr.Link \_\_\_\_\_  
Lexis/Nexis \_\_\_\_\_  
Sequence Systems \_\_\_\_\_  
WWW/Internet \_\_\_\_\_  
Other (specify) \_\_\_\_\_

BEST AVAILABLE COPY

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:41:58 ON 31 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 AUG 2000 HIGHEST RN 287950-86-1  
 DICTIONARY FILE UPDATES: 30 AUG 2000 HIGHEST RN 287950-86-1


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
 for details.

=> d sta que 18

L1 STR



NODE ATTRIBUTES:


NSPEC IS RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 7  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L3 23367 SEA FILE=REGISTRY SSS FUL L1  
 L6 STR



VAR G1=2/1/6/5

NODE ATTRIBUTES:

NSPEC IS RC AT 12  
 NSPEC IS RC AT 17  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 9

Point of Contact:  
 Librarian-Floyd L. Anderson  
 CM1 1E01 Tel: 508-4498

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L8 5 SEA FILE=REGISTRY SUB=L3 SSS FUL L6

100.0% PROCESSED 1081 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

=> d his l15-

(FILE 'REGISTRY' ENTERED AT 09:02:11 ON 31 AUG 2000)

FILE 'HCAOLD' ENTERED AT 09:40:52 ON 31 AUG 2000

L15 0 S L8

FILE 'HCAPLUS' ENTERED AT 09:40:56 ON 31 AUG 2000

L16 3 S L8

FILE 'USPATFULL' ENTERED AT 09:41:40 ON 31 AUG 2000

L17 0 S L8

FILE 'REGISTRY' ENTERED AT 09:41:58 ON 31 AUG 2000

=> d ide can l8 tot

L8 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2000 ACS


RN 236416-02-7 REGISTRY

CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

MF C26 H33 N7 O4 . 2 Cl H

SR CA

LC STN Files: CA, CAPLUS



● 2 HCl

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:157771

REFERENCE 2: 131:157761


L8 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2000 ACS

RN 189044-40-4 REGISTRY

CN 1H-Benzimidazole-4-carboxamide, N-(2,6-dichlorophenyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C21 H17 Cl2 F3 N4 O3  
 SR CA  
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:293352


L8 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2000 ACS  
 RN 189044-25-5 REGISTRY  
 CN 1H-Benzimidazole-4-carboxamide, N-(2,6-dimethylphenyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)  
 MF C23 H23 F3 N4 O3  
 SR CA  
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:293352


L8 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2000 ACS  
 RN 189044-24-4 REGISTRY  
 CN 1H-Benzimidazole-4-carboxamide, N-(2-methoxy-6-methylphenyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C23 H23 F3 N4 O4  
 SR CA  
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:293352

L8 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2000 ACS  
RN 189044-23-3 REGISTRY  
CN 1H-Benzimidazole-4-carboxamide, N-(2-chloro-6-methylphenyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H20 Cl F3 N4 O3  
SR CA  
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:293352

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 09:42:16 ON 31 AUG 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 31 Aug 2000 VOL 133 ISS 9  
FILE LAST UPDATED: 29 Aug 2000 (20000829/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.

=> d all tot 116

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:511140 HCAPLUS

DN 131:157771

TI Preparation of five-membered, benzo-condensed heterocycles as antithrombotics

IN Ries, Uwe; Hauel, Norbert; Mihm, Gerhard; Priepe, Henning; Binder, Klaus; Stassen, Jean Marie; Wienen, Wolfgang; Zimmermann, Rainer

PA Boehringer Ingelheim Pharma Kg, Germany

SO PCT Int. Appl., 250 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM C07D235-16


ICS A61K031-415; C07D403-12; C07D413-14; C07D401-06; C07D413-06;  
C07D401-12; C07D403-14; C07D263-56; C07D277-64; C07D209-18;  
C07D307-81; C07D405-12; C07D405-14; C07F009-32

CC 28-20 (Heterocyclic Compounds (More Than One Hetero Atom))


Section cross-reference(s): 1, 25

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940072	A1	19990812	WO 1999-EP537	19990128
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 19804085	A1	19990805	DE 1998-19804085	19980203
	DE 19834325	A1	20000217	DE 1998-19834325	19980730
	AU 9927201	A1	19990823	AU 1999-27201	19990128
PRAI	DE 1998-19804085		19980203		
	DE 1998-19834325		19980730		
	WO 1999-EP537		19990128		
OS	MARPAT 131:157771				
GI					



I



II

AB Title compds. [I; R = 5-C6H5SO2NH, 6-C6H5SO2NH, 5-C6H5NHSO2, 5-C6H5SO2N(CH2COOEt), 5-C6H5SO2N(CH3), 5-C6H5N(CH2CH2CH2COOEt)CO, 5-C6H5, CH3N(C6H5)CO, 8; R1 = H, 7-CH3, 3-Br, 3-EtO; R2 = C(:NH)NH2; A = CH2, NH; X = CH, MeN, EtOCOCH2CH2N, O, S, NCH2CO2H; Y = N, CH, CH:CH; Z = CH, N; dotted bond = single, double in relation to X; A is attached at 2, or 8 position depending on the heterocyclic ring] and their tautomers, stereoisomers, mixts. and their physiol. compatible salts with inorg. or org. acids or bases are prepd. and title compds in which R2 is a cyano group, present valuable intermediate products for the prodn. of the remaining compds. of the general formula I, with R2 is amidino, which have valuable pharmacol. properties, esp. an antithrombotic activity. Thus, the title compd. II was prepd.

ST benzimidazolylmethylbenzamidine benzimidazolylaminobenzamidine benzthiazolylmethylbenzamidine indolylmethylbenzamidine prepn antithrombotic; benzofuranylmethylbenzamidine

IT quinolinylsulfonylaminobenzthiazolylmethylbenzamidine prepn antithrombotic Anticoagulants

(prepn. of five-membered benzo-condensed heterocycles as antithrombotics)

IT 236414-44-1P 236416-44-7P 236416-45-8P 236416-63-0P 236416-89-0P  
236417-16-6P 236418-65-8P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of five-membered benzo-condensed heterocycles as antithrombotics)

IT 236414-28-1P 236414-29-2P 236414-31-6P 236414-32-7P 236414-34-9P  
236414-36-1P 236414-38-3P 236414-40-7P 236414-42-9P 236414-45-2P  
236414-46-3P 236414-47-4P 236414-48-5P 236414-49-6P 236414-51-0P  
236414-52-1P 236414-53-2P 236414-54-3P 236414-55-4P 236414-56-5P  
236414-57-6P 236414-59-8P 236414-60-1P 236414-61-2P 236414-62-3P  
236414-63-4P 236414-65-6P 236414-67-8P 236414-68-9P 236414-69-0P  
236414-70-3P 236414-71-4P 236414-72-5P 236414-73-6P 236414-75-8P  
236414-76-9P 236414-77-0P 236414-78-1P 236414-79-2P 236414-80-5P  
236414-81-6P 236414-82-7P 236414-84-9P 236414-85-0P 236414-86-1P  
236414-87-2P 236414-88-3P 236414-89-4P 236414-91-8P 236414-92-9P  
236414-93-0P 236414-94-1P 236414-95-2P 236414-96-3P 236414-97-4P  
236414-98-5P 236415-00-2P 236415-01-3P 236415-02-4P 236415-03-5P  
236415-04-6P 236415-05-7P 236415-06-8P 236415-07-9P 236415-08-0P  
236415-09-1P 236415-10-4P 236415-11-5P 236415-12-6P 236415-13-7P  
236415-14-8P 236415-15-9P 236415-16-0P 236415-18-2P 236415-19-3P  
236415-20-6P 236415-21-7P 236415-22-8P 236415-23-9P 236415-24-0P  
236415-25-1P 236415-26-2P 236415-28-4P 236415-29-5P 236415-30-8P  
236415-31-9P 236415-32-0P 236415-34-2P 236415-35-3P 236415-36-4P  
236415-37-5P 236415-38-6P 236415-39-7P 236415-40-0P 236415-42-2P  
236415-43-3P 236415-44-4P 236415-45-5P 236415-46-6P 236415-48-8P

236415-49-9P	236415-50-2P	236415-51-3P	236415-52-4P	236415-53-5P
236415-55-7P	236415-56-8P	236415-57-9P	236415-58-0P	236415-59-1P
236415-60-4P	236415-62-6P	236415-63-7P	236415-64-8P	236415-65-9P
236415-66-0P	236415-67-1P	236415-68-2P	236415-69-3P	236415-70-6P
236415-72-8P	236415-73-9P	236415-74-0P	236415-75-1P	236415-76-2P
236415-77-3P	236415-78-4P	236415-80-8P	236415-81-9P	236415-82-0P
236415-83-1P	236415-84-2P	236415-85-3P	236415-86-4P	236415-87-5P
236415-88-6P	236415-89-7P	236415-90-0P	236415-91-1P	236415-93-3P
236415-94-4P	236415-95-5P	236415-96-6P	236415-97-7P	236415-98-8P
236415-99-9P	236416-01-6P	<b>236416-02-7P</b>	236416-03-8P	
236416-04-9P	236416-05-0P	236416-06-1P	236416-07-2P	236416-08-3P
236416-10-7P	236416-11-8P	236416-12-9P	236416-13-0P	236416-14-1P
236416-15-2P	236416-16-3P	236416-17-4P	236416-18-5P	236416-19-6P
236416-21-0P	236416-22-1P	236416-23-2P	236416-24-3P	236416-25-4P
236416-26-5P	236416-27-6P	236416-28-7P	236416-29-8P	236416-30-1P
236416-31-2P	236416-32-3P	236416-33-4P	236416-34-5P	236416-35-6P
236416-36-7P	236416-37-8P	236416-38-9P	236416-39-0P	236416-40-3P
236416-41-4P	236416-42-5P	236416-43-6P	236416-46-9P	236416-47-0P
236416-48-1P	236416-49-2P	236416-50-5P	236416-51-6P	236416-52-7P
236416-53-8P	236416-54-9P	236416-55-0P	236416-56-1P	236416-57-2P
236416-58-3P	236416-59-4P	236416-60-7P	236416-61-8P	236416-62-9P
236416-64-1P	236416-65-2P	236416-66-3P	236416-67-4P	236416-68-5P
236416-69-6P	236416-70-9P	236416-71-0P	236416-72-1P	236416-73-2P
236416-74-3P	236416-75-4P	236416-76-5P	236416-77-6P	236416-78-7P
236416-79-8P	236416-80-1P	236416-81-2P	236416-82-3P	236416-83-4P
236416-84-5P	236416-85-6P	236416-86-7P	236416-87-8P	236416-88-9P
236416-90-3P	236416-91-4P	236416-92-5P	236416-93-6P	236416-94-7P
236416-95-8P	236416-96-9P	236416-97-0P		

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of five-membered benzo-condensed heterocycles as antithrombotics)

IT	236416-98-1P	236416-99-2P	236417-00-8P	236417-01-9P	236417-02-0P
	236417-03-1P	236417-04-2P	236417-05-3P	236417-06-4P	236417-07-5P
	236417-08-6P	236417-09-7P	236417-10-0P	236417-11-1P	236417-12-2P
	236417-13-3P	236417-14-4P	236417-15-5P	236417-17-7P	236417-18-8P
	236417-19-9P	236417-20-2P	236417-21-3P	236417-22-4P	236417-23-5P
	236417-24-6P	236417-25-7P			

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of five-membered benzo-condensed heterocycles as antithrombotics)

IT	67-63-0, Isopropanol, reactions	99-56-9, 4-Nitro-o-phenylenediamine
	100-02-7, 4-Nitrophenol, reactions	107-10-8, n-Propylamine, reactions
	108-90-7, Chlorobenzene, reactions	110-53-2, n-Pentylbromide
	120-92-3, Cyclopentanone	122-01-0, 4-Chloro-benzoyl chloride
	134-32-7, 1-Naphthylamine	364-76-1, 4-Fluoro-3-nitroaniline
	369-36-8, 2-Fluoro-5-nitroaniline	407-25-0, Trifluoroacetic acid anhydride
	553-86-6, 2(3H)-Benzofuranone	603-76-9, N-Methylindole
	623-33-6, 628-77-3, 1,5-Diodopentane	635-22-3, 4-Chloro-3-nitroaniline
	873-74-5, 4-Aminobenzonitrile	1068-90-2, Acetamidomalonic acid diethyl ester
	1461-22-9, Tributyltin chloride	2719-27-9, Cyclohexanecarbonyl chloride
	3984-34-7, 4509-90-4, 5-Bromo-4-oxopentanoic acid	5393-46-4, 5462-71-5, 4-Cyanophenylacetic acid
	10025-87-3, Phosphoric trichloride	16419-60-6, 2-Tolylboric acid
	17201-43-3, 4-Bromomethylbenzonitrile	20430-33-5, 4-Cyanobenzyl triphenylphosphonium chloride
	23249-97-0, 2-Benzimidazolepropionic acid	38136-29-7, 50893-53-3, 52605-49-9, Sarcosine ethyl ester hydrochloride
	52798-01-3, 236418-59-0, 236418-60-3, 236418-62-5, 236418-64-7	

RL: RCT (Reactant)

(prepn. of five-membered benzo-condensed heterocycles as antithrombotics)

IT	137-49-5P	2373-43-5P	3277-80-3P	6315-23-7P	7019-01-4P
	15965-66-9P	19202-19-8P	22585-81-5P	22888-47-7P	25877-78-5P
	36942-34-4P	38818-50-7P, 4-Chloro-3-nitro-benzoyl chloride	41939-61-1P		
	43229-87-4P	52117-01-8P	66315-37-5P	68502-17-0P	91955-91-8P



101623-69-2P	104388-73-0P	105402-34-4P	157427-46-8P	198879-98-0P
211915-89-8P	211915-90-1P	211915-91-2P	211915-92-3P	211915-93-4P
236417-26-8P	236417-27-9P	236417-28-0P	236417-29-1P	236417-30-4P
236417-31-5P	236417-32-6P	236417-33-7P	236417-34-8P	236417-35-9P
236417-36-0P	236417-37-1P	236417-38-2P	236417-39-3P	236417-40-6P
236417-41-7P	236417-42-8P	236417-43-9P	236417-44-0P	236417-45-1P
236417-46-2P	236417-47-3P	236417-48-4P	236417-49-5P	236417-50-8P
236417-51-9P	236417-52-0P	236417-53-1P	236417-54-2P	236417-55-3P
236417-56-4P	236417-57-5P	236417-58-6P	236417-59-7P	236417-60-0P
236417-61-1P	236417-62-2P	236417-63-3P	236417-64-4P	236417-65-5P
236417-66-6P	236417-67-7P	236417-68-8P	236417-69-9P	236417-70-2P
236417-71-3P	236417-72-4P	236417-73-5P	236417-74-6P	236417-75-7P
236417-76-8P	236417-77-9P	236417-78-0P	236417-79-1P	236417-80-4P
236417-81-5P	236417-82-6P	236417-83-7P	236417-85-9P	236417-87-1P
236417-88-2P	236417-89-3P	236417-90-6P	236417-91-7P	236417-92-8P
236417-93-9P	236417-94-0P	236417-95-1P	236417-96-2P	236417-97-3P
236417-98-4P	236417-99-5P	236418-00-1P	236418-01-2P	236418-02-3P
236418-03-4P	236418-04-5P	236418-05-6P	236418-06-7P	236418-07-8P
236418-08-9P	236418-09-0P	236418-10-3P	236418-11-4P	236418-12-5P
236418-13-6P	236418-14-7P	236418-15-8P	236418-16-9P	236418-17-0P
236418-18-1P	236418-19-2P	236418-20-5P	236418-21-6P	236418-22-7P
236418-23-8P	236418-24-9P	236418-25-0P	236418-26-1P	236418-27-2P
236418-28-3P	236418-29-4P	236418-30-7P	236418-31-8P	236418-32-9P
236418-33-0P	236418-34-1P	236418-35-2P	236418-36-3P	236418-37-4P
236418-38-5P	236418-39-6P	236418-40-9P	236418-41-0P	236418-42-1P
236418-43-2P	236418-44-3P	236418-45-4P	236418-46-5P	236418-47-6P
236418-48-7P	236418-49-8P	236418-50-1P	236418-51-2P	236418-52-3P
236418-53-4P	236418-54-5P	236418-55-6P	236418-56-7P	236418-57-8P
236418-58-9P	236418-61-4P	236418-63-6P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of five-membered benzo-condensed heterocycles as  
antithrombotics)

RE.CNT 10

RE

- (1) Boehringer Ingelheim Pharma Kg; DE 19718181 A 1998
- (2) Boehringer Ingelheim Pharma Kg; WO 9837075 A 1998
- (3) Boehringer Mannheim GmbH; EP 0223937 A 1987
- (4) Boehringer Mannheim GmbH; EP 0275888 A 1988
- (5) Daiichipharmaceutical Co Ltd; EP 0540051 A 1993
- (6) Dr Karl Thomae GmbH; EP 0531883 A 1993
- (7) Dr Karl Thomae GmbH; EP 0567966 A 1993
- (8) Eli Lilly And Company; EP 0655439 A 1995
- (9) McNeil-Ppc Inc; US 5342851 A 1994 HCAPLUS
- (10) Nagahara, T; J MED CHEM 1994, V37(8), P1200 HCAPLUS

L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:505930 HCAPLUS

DN 131:157761

TI 5-Membered heterocyclic condensed benzo derivatives, their preparation,  
and their use as drugs

IN Ries, Uwe; Huel, Norbert; Mihm, Gerhard; Priepke, Henning; Binder, Klaus;  
Stassen, Jean Marie; Wienen, Wolfgang; Zimmermann, Rainer

PA Boehringer Ingelheim Pharma K.-G., Germany

SO Ger. Offen., 94 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM C07D235-14

ICS C07D235-20; C07D401-12; C07D403-12; C07D413-14; C07D405-12;  
C07D417-12; C07D277-28; C07D263-56; C07D307-81; C07D209-14;  
A61K031-33

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----

PI DE 19804085 A1 19990805 DE 1998-19804085 19980203  
 WO 9940072 A1 19990812 WO 1999-EP537 19990128  
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
 DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
 TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9927201 A1 19990823 AU 1999-27201 19990128  
 PRAI DE 1998-19804085 19980203  
 DE 1998-19834325 19980730  
 WO 1999-EP537 19990128  
 OS MARPAT 131:157761  
 AB Approx. 300 antithrombotic title compds. such as 4-[5-[N-(8-quinolylsulfonyl)-N-(carboxymethyl)amino]-1-methyl-1H-benzimidazol-2-ylmethyl]benzamidinium hydrochloride (I), 4-[5-[N-(benzenesulfonyl)-N-(2-(dimethylamino)ethyl)amino]-1-benzyl-1H-benzimidazol-2-ylmethyl]benzamidinium dihydrochloride, 4-[5-[N-(3-carboxypropionyl)-N-(cyclopentyl)amino]-1-methyl-1H-benzimidazol-2-ylmethyl]benzamidinium hydrochloride (II), and 4-[5-[N-(8-quinolylsulfonyl)-N-(carboxymethyl)amino]-1-methyl-1H-benzothiazol-2-ylmethyl]benzamidinium hydrochloride were prep'd. by std. methods. The ED200 in .mu.M for I was 0.92 and for II was 0.82. Formulations for the antithrombotics were given.  
 ST antithrombotic benzimidazolylmethylbenzamidinium prepn; benzamidinium benzimidazolyl benzothiazolyl prepn  
 IT Anticoagulants  
 (prepn. and antithrombotic activity of benzimidazolylmethylbenzamidines)  
 IT 237750-48-0P 237750-49-1P 237750-50-4P 237750-51-5P 237750-52-6P  
 237750-53-7P 237750-54-8P 237750-55-9P 237750-56-0P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and antithrombotic activity of benzimidazolylmethylbenzamidines)  
 IT 62-53-3, Benzenamine, reactions 78-81-9, Isobutylamine 96-99-1,  
 4-Chloro-3-nitrobenzoic acid 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 98-09-9, Benzenesulfonyl chloride 99-56-9,  
 4-Nitro-o-phenylenediamine 100-02-7, 4-Nitrophenol, reactions 105-36-2, Ethyl bromoacetate 107-10-8, 1-Propanamine, reactions 108-30-5, reactions 108-90-7, Chlorobenzene, reactions 109-04-6,  
 2-Bromopyridine 110-53-2, 1-Bromopentane 119-34-6,  
 4-Hydroxy-3-nitroaniline 120-92-3, Cyclopentanone 123-75-1, Pyrrolidine, reactions 134-32-7, 1-Naphthylamine 364-76-1,  
 4-Fluoro-3-nitroaniline 369-36-8, 2-Fluoro-5-nitroaniline 501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 553-86-6,  
 2(3H)-Benzofuranone 603-76-9, 1-Methylindole 623-33-6, Glycine ethyl ester hydrochloride 623-48-3, Ethyl iodoacetate 635-22-3,  
 4-Chloro-3-nitroaniline 645-88-5, Carboxymethoxyamine 873-74-5,  
 4-Aminobenzonitrile 1068-90-2, Diethyl acetamidomalonate 1146-39-0  
 1461-22-9, Tributyltin chloride 1528-41-2, Ethyl 4-cyanophenylacetate 1569-69-3, Cyclohexyl mercaptan 1878-66-6, 4-Chlorophenylacetic acid 2719-27-9, Cyclohexanecarbonyl chloride 3984-34-7, 4-(4-Chlorophenyl)-4-oxobutyric acid 4509-90-4, 5-Bromovaleryl chloride 4801-27-8,  
 2-Bromoethyl chloroformate 5292-43-3, tert-Butyl bromoacetate 5393-46-4, 2-Nitro-4-phenylacetanilide 5462-71-5, 4-Cyanophenylacetic acid 7452-59-7, n-Octyl chloroformate 13248-54-9, Cyclohexyl chloroformate 15441-07-3, Methyl 3-(chlorosulfonyl)propionate 16419-60-6, o-Tolylboronic acid 17201-43-3, 4-Cyanobenzyl bromide 18704-37-5, 8-Quinolinesulfonyl chloride 20430-33-5,  
 4-Cyanobenzyltriphenylphosphonium chloride 21535-97-7,  
 3-Methylbenzofuran 23249-97-0, 3-(2-Benzimidazolyl)propionic acid 38136-29-7, 4-Methylpentanoyl chloride 49665-74-9, 2-Chloromethyl-1-methylpiperidine 50479-22-6, tert-Butyl 4-aminobutyrate 50893-53-3,

1-Chloroethyl chloroformate 52605-49-9, Sarcosine ethyl ester hydrochloride 53298-30-9, 2-Methylsulfonyl ethyl 4-nitrophenyl carbonate 64399-27-5, 1-(4-Chlorophenyl)-1-cyclopropanecarbonitrile 72934-37-3, 1-(4-Chlorophenyl)cyclopropanecarboxylic acid 187160-68-5, 4-Chloro-3-nitrobenzyl methanesulfonate 236414-82-7 236417-58-6 236418-60-3 236418-62-5 237750-73-1 237750-74-2 237750-75-3 237750-76-4 237750-77-5 237750-78-6 237750-79-7 237750-80-0 237750-81-1 237750-82-2 237750-83-3 237750-84-4 237750-85-5 237750-86-6 237750-87-7 237750-88-8 237750-89-9 237750-90-2 237750-91-3 237750-92-4 237750-93-5 237750-94-6 237750-95-7 237750-96-8 237750-97-9 237750-98-0 237750-99-1 237751-00-7 237751-01-8 237751-02-9 237751-03-0 237751-04-1 237751-05-2 237751-06-3 237751-07-4 237751-08-5 237751-09-6 237751-10-9 237751-11-0 237751-12-1 237751-13-2 237751-14-3 237751-15-4 237751-16-5 237751-17-6 237751-18-7 237751-19-8 237751-20-1 237751-21-2 237751-22-3 237751-23-4 237751-24-5 237751-25-6 237751-26-7 237751-27-8 237751-28-9 237751-29-0 237751-30-3 237751-31-4 237751-32-5 237751-33-6 237751-34-7 237751-35-8 237751-36-9 237751-37-0 237751-38-1 237751-39-2 237751-40-5 237751-41-6 237751-42-7 237751-43-8 237751-44-9 237751-45-0 237751-46-1 237751-47-2 237751-48-3 237751-49-4 237751-50-7 237751-51-8 237751-52-9 237751-53-0 237751-54-1 237751-55-2 237751-56-3 237751-57-4 237751-58-5 237751-59-6 237751-60-9 237751-61-0 237751-62-1 237751-63-2 237751-64-3 237751-65-4 237751-66-5 237751-67-6 237751-68-7 237751-69-8 237751-70-1 237751-71-2 237751-72-3 237751-73-4 237751-74-5 237751-75-6 237751-76-7 237751-77-8 237751-78-9 237751-79-0, 4-(5-Bromo-2-benzothiazolylmethyl)benzonitrile 237751-80-3 237751-81-4 237751-82-5 237751-83-6 237751-84-7 237751-85-8 237751-86-9 237751-87-0 237751-88-1 237751-89-2 237751-90-5 237751-91-6 237751-92-7 237751-93-8 237751-94-9 237751-95-0 237751-96-1 237751-97-2 237751-98-3 237751-99-4 237752-00-0 237752-01-1 237752-02-2 237752-03-3 237752-04-4 237752-05-5 237752-06-6 237752-07-7 237752-08-8 237752-09-9 237752-10-2 237752-11-3 237752-12-4 237752-13-5 237752-14-6 237752-15-7 237752-16-8 237752-17-9 237752-18-0 237752-19-1 237752-20-4 237752-21-5 237752-22-6 237752-23-7 237752-24-8 237752-25-9 237752-26-0 237752-27-1 237752-28-2 237752-29-3

RL: RCT (Reactant)

(prepn. and antithrombotic activity of benzimidazolylmethylbenzamides)

IT 137-49-5P 1005-33-0P, Dichloro(4-chlorophenyl)phosphine 3277-80-3P, 4-(Cyclohexylcarbonyl)chlorobenzene 6315-23-7P, Ethyl 3-(1H-benzimidazol-2-yl)propionate 7019-01-4P, 4-Phenylsulfonylaniline 15965-66-9P, 1-Methyl-2-chloro-5-nitrobenzimidazole 19202-19-8P, 2-(4-Chlorophenyl)-1-(1-pyrrolidinyl)ethanone 20355-97-9P, Diethyl (4-chlorophenyl)phosphonite 22888-47-7P 25877-78-5P, N-Methyl-2-nitro-4-phenylaniline 36942-34-4P, 4-Benzenesulfonylamino-2-nitrophenol 38818-50-7P, 4-Chloro-3-nitrobenzoyl chloride 41939-61-1P, 2-Methylamino-5-nitroaniline 43229-87-4P 52117-01-8P 66108-85-8P, 1-Methyl-5-nitro-2-benzimidazolone 66315-37-5P 68502-17-0P, N-(2-Amino-4-phenylsulfonylphenyl)-N-methylamine 91955-91-8P, N-(2-Nitro-4-phenylsulfonylphenyl)-N-methylamine 101623-68-1P 101623-69-2P, 1-Chloroethyl 4-nitrophenyl carbonate 104388-73-0P, 4-Benzenesulfonylamino-2-aminophenol 105402-34-4P 157427-46-8P, 2-Tributylstannyl-1-methyl-1H-indole 198879-98-0P 211915-89-8P 211915-90-1P 211915-91-2P 211915-92-3P 211915-93-4P 236414-44-1P 236414-46-3P 236414-71-4P 236414-72-5P 236414-78-1P 236414-89-4P 236415-12-6P 236415-16-0P 236415-22-8P 236415-28-4P 236415-39-7P 236415-43-3P 236415-48-8P 236415-56-8P 236415-57-9P 236415-62-6P 236415-63-7P 236415-67-1P 236415-68-2P 236415-82-0P 236415-85-3P 236415-86-4P 236415-87-5P 236415-90-0P 236415-94-4P 236415-95-5P 236416-04-9P 236416-05-0P 236416-11-8P 236416-12-9P 236416-15-2P 236416-16-3P 236416-21-0P 236416-35-6P 236416-44-7P 236416-45-8P 236416-63-0P 236416-75-4P 236416-89-0P 236416-90-3P 236416-92-5P 236416-94-7P 236416-97-0P 236417-10-0P 236417-14-4P 236417-16-6P

236417-18-8P 236417-20-2P 236417-26-8P 236417-27-9P 236417-28-0P  
 236417-29-1P 236417-30-4P 236417-31-5P 236417-32-6P 236417-33-7P  
 236417-34-8P 236417-35-9P 236417-36-0P 236417-38-2P 236417-39-3P  
 236417-40-6P 236417-41-7P 236417-42-8P 236417-44-0P 236417-45-1P  
 236417-46-2P 236417-47-3P 236417-50-8P 236417-51-9P,  
 4-(Cyclohexylcarbonyl)-2-nitrochlorobenzene 236417-52-0P,  
 4-(Cyclohexylcarbonyl)-N-methyl-2-nitroaniline 236417-53-1P  
 236417-54-2P 236417-57-5P 236417-59-7P, Ethyl (4-  
 chlorophenyl)(pentyl)phosphinate 236417-60-0P 236417-61-1P  
 236417-62-2P 236417-63-3P 236417-64-4P 236417-65-5P 236417-66-6P  
 236417-67-7P 236417-68-8P 236417-69-9P 236417-70-2P 236417-71-3P  
 236417-72-4P 236417-73-5P 236417-74-6P 236417-75-7P 236417-76-8P,  
 N-Methyl-2-nitro-4-phenylacetanilide 236417-77-9P, 2-Amino-N-methyl-4-  
 phenylaniline 236417-78-0P 236417-79-1P 236417-80-4P 236417-81-5P  
 236417-82-6P 236417-83-7P 236417-85-9P 236417-87-1P 236417-88-2P  
 236417-89-3P 236417-90-6P 236417-91-7P 236417-92-8P,  
 N-(4-Phenylsulfonylphenyl)methanesulfonamide 236417-93-9P,  
 N-(2-Nitro-4-phenylsulfonylphenyl)methanesulfonamide 236417-94-0P,  
 N-(2-Nitro-4-phenylsulfonylphenyl)-N-methylmethanesulfonamide  
 236417-95-1P 236417-96-2P, N-Cyclopentyl-4-fluoro-3-nitroaniline  
 236417-97-3P, N-Cyclopentyl-4-methylamino-3-nitroaniline 236417-98-4P  
 236417-99-5P 236418-00-1P 236418-01-2P, 1-(4-Chlorophenyl)-4-methyl-1-  
 pentanone 236418-02-3P 236418-03-4P, 5-(4-Chlorophenyl)-4-isobutyl-1H-  
 imidazole 236418-04-5P 236418-05-6P 236418-06-7P 236418-07-8P  
 236418-08-9P 236418-09-0P 236418-10-3P 236418-11-4P 236418-12-5P  
 236418-13-6P 236418-16-9P 236418-17-0P 236418-18-1P 236418-19-2P  
 236418-20-5P 236418-21-6P 236418-23-8P 236418-24-9P 236418-25-0P  
 236418-26-1P 236418-27-2P 236418-28-3P 236418-29-4P 236418-30-7P  
 236418-31-8P 236418-32-9P 236418-33-0P 236418-34-1P 236418-35-2P,  
 4-(1-Methyl-1H-indol-2-yl)methylbenzonitrile 236418-36-3P 236418-37-4P  
 236418-38-5P 236418-40-9P, 2-Tributylstannyl-3-methylbenzofuran  
 236418-41-0P, 4-(3-Methylbenzofuran-2-ylmethyl)benzonitrile  
 236418-42-1P, 4-(3-Methyl-6-nitrobenzofuran-2-ylmethyl)benzonitrile  
 236418-43-2P, 4-(6-Amino-3-methylbenzofuran-2-ylmethyl)benzonitrile  
 236418-44-3P 236418-45-4P, 4-(2-Benzofuranylmethyl)benzonitrile  
 236418-46-5P, 4-(3-Bromo-2-benzofuranylmethyl)benzonitrile 236418-47-6P,  
 4-(3-Bromo-6-nitro-2-benzofuranylmethyl)benzonitrile 236418-48-7P,  
 4-(6-Amino-3-bromo-2-benzofuranylmethyl)benzonitrile 236418-49-8P  
 236418-50-1P 236418-51-2P 236418-52-3P 236418-53-4P 236418-54-5P  
 236418-55-6P 236418-56-7P 236418-57-8P 236418-58-9P 236418-61-4P  
 236418-63-6P 237750-36-6P 237750-40-2P 237750-44-6P 237750-60-6P  
 237750-65-1P 237750-66-2P 237750-67-3P, 2-Amino-4-(cyclohexylcarbonyl)-  
 N-methylaniline 237750-68-4P 237750-69-5P 237750-70-8P  
 237750-71-9P 237750-72-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and antithrombotic activity of benzimidazolylmethylbenzamides)

IT	236414-28-1P	236414-29-2P	236414-31-6P	236414-32-7P	236414-34-9P
	236414-36-1P	236414-38-3P	236414-40-7P	236414-42-9P	236414-45-2P
	236414-47-4P	236414-48-5P	236414-49-6P	236414-51-0P	236414-52-1P
	236414-53-2P	236414-54-3P	236414-55-4P	236414-56-5P	236414-57-6P
	236414-59-8P	236414-61-2P	236414-62-3P	236414-63-4P	236414-67-8P
	236414-68-9P	236414-69-0P	236414-70-3P	236414-73-6P	236414-76-9P
	236414-77-0P	236414-79-2P	236414-80-5P	236414-81-6P	236414-84-9P
	236414-85-0P	236414-86-1P	236414-87-2P	236414-88-3P	236414-91-8P
	236414-92-9P	236414-93-0P	236414-94-1P	236414-95-2P	236414-96-3P
	236414-97-4P	236414-98-5P	236415-01-3P	236415-02-4P	236415-03-5P
	236415-04-6P	236415-05-7P	236415-07-9P	236415-08-0P	236415-09-1P
	236415-10-4P	236415-11-5P	236415-13-7P	236415-14-8P	236415-15-9P
	236415-18-2P	236415-19-3P	236415-20-6P	236415-21-7P	236415-23-9P
	236415-24-0P	236415-25-1P	236415-30-8P	236415-31-9P	236415-32-0P
	236415-34-2P	236415-35-3P	236415-36-4P	236415-38-6P	236415-40-0P
	236415-42-2P	236415-44-4P	236415-45-5P	236415-46-6P	236415-49-9P
	236415-50-2P	236415-51-3P	236415-52-4P	236415-53-5P	236415-55-7P
	236415-58-0P	236415-59-1P	236415-60-4P	236415-64-8P	236415-65-9P
	236415-66-0P	236415-69-3P	236415-70-6P	236415-72-8P	236415-73-9P

236415-74-0P 236415-75-1P 236415-76-2P 236415-77-3P 236415-78-4P  
236415-80-8P 236415-81-9P 236415-83-1P 236415-84-2P 236415-88-6P  
236415-89-7P 236415-91-1P 236415-93-3P 236415-96-6P 236415-97-7P  
236415-98-8P 236415-99-9P 236416-01-6P **236416-02-7P**  
236416-03-8P 236416-06-1P 236416-07-2P 236416-10-7P 236416-13-0P  
236416-14-1P 236416-17-4P 236416-18-5P 236416-19-6P 236416-22-1P  
236416-23-2P 236416-24-3P 236416-25-4P 236416-26-5P 236416-28-7P  
236416-29-8P 236416-30-1P 236416-32-3P 236416-34-5P 236416-36-7P  
236416-37-8P 236416-38-9P 236416-39-0P 236416-40-3P 236416-41-4P  
236416-42-5P 236416-43-6P 236416-46-9P 236416-47-0P 236416-48-1P  
236416-49-2P 236416-50-5P 236416-51-6P 236416-53-8P 236416-54-9P  
236416-55-0P 236416-56-1P 236416-57-2P 236416-58-3P 236416-59-4P  
236416-61-8P 236416-62-9P 236416-64-1P 236416-65-2P 236416-66-3P  
236416-67-4P 236416-68-5P 236416-69-6P 236416-70-9P 236416-71-0P  
236416-72-1P 236416-73-2P 236416-74-3P 236416-76-5P 236416-77-6P  
236416-78-7P 236416-79-8P 236416-80-1P 236416-81-2P 236416-82-3P  
236416-83-4P 236416-84-5P 236416-85-6P 236416-86-7P 236416-87-8P  
236416-88-9P 236416-91-4P 236416-93-6P 236416-95-8P 236416-96-9P  
236416-98-1P 236416-99-2P 236417-00-8P 236417-01-9P 236417-02-0P  
236417-03-1P 236417-04-2P 236417-05-3P 236417-06-4P 236417-07-5P  
236417-08-6P 236417-09-7P 236417-11-1P 236417-12-2P 236417-13-3P  
236417-15-5P 236417-17-7P 236417-19-9P 236417-21-3P 236417-22-4P  
236417-23-5P 236418-65-8P 237750-33-3P 237750-35-5P 237750-37-7P  
237750-38-8P 237750-39-9P 237750-41-3P 237750-42-4P 237750-43-5P  
237750-45-7P 237750-46-8P 237750-47-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and antithrombotic activity of benzimidazolylmethylbenzamidines  
)

L16 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:315042 HCAPLUS

DN 126:293352

TI Preparation of benzimidazoles for the prevention and/or the treatment of  
bone diseases

IN Oku, Teruo; Kawai, Yoshio; Yatabe, Takumi; Sato, Shigeki; Yamazaki,  
Hitoshi; Kayakiri, Natsuko; Yoshihara, Kousei

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Oku, Teruo; Kawai, Yoshio;  
Yatabe, Takumi; Sato, Shigeki; Yamazaki, Hitoshi; Kayakiri, Natsuko;  
Yoshihara, Kousei

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D235-06


ICS A61K031-415; C07D235-08; C07D235-10; C07D235-12; C07D235-24;  
C07D235-26; C07D235-28; C07D401-06; C07D401-12; C07D403-06;  
C07D403-12; C07D407-06

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 9710219	A1	19970320	WO 1996-JP2530	19960905
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	863881	A1	19980916	EP 1996-929540	19960905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP	11513364	T2	19991116	JP 1996-511824	19960905
PRAI	GB 1995-18552		19950911		
	WO 1996-JP2530		19960905		
OS	MARPAT 126:293352				
GI					



AB The title compds. [I; R1 = acyl, (un)substituted lower alkenyl, lower alkyl; R2 = H, lower alkyl, lower alkoxy, etc.; R1R2 = lower alkylene, lower alkenylene (may include O, S, NH, N-alkyl); R3 = H, halo; R4 = (un)substituted heterocyclyl, aryl; A = CONR9, N(R10)CO (wherein R9, R10 = H, (un)substituted lower alkyl)], and their pharmaceutically acceptable salts, inhibitors of bone resorption and bone metab., were prepd. Thus, hydrogenation of 1,2-dimethyl-4-nitro-1H-benzimidazole over 10% Pd/C in MeOH followed by reaction of the resulting 4-amino-1,2-dimethyl-1H-benzimidazole with 2,6-dichlorobenzoyl chloride in the presence of Et3N in ethylene chloride afforded I [R1, R2 = Me; R3 = H; R4 = 2,6-Cl2C6H3; A = NHCO]. Compds. I are effective at 0.1-1000 mg/body/day.

ST benzimidazole prepn bone disease resorption metab

IT Metabolic diseases

(bone, inhibitors; prepn. of benzimidazoles for the prevention and/or the treatment of bone diseases)

IT Bone diseases

(metabolic, inhibitors; prepn. of benzimidazoles for the prevention and/or the treatment of bone diseases)

IT Bone diseases

Bone resorption inhibitors

(prepn. of benzimidazoles for the prevention and/or the treatment of bone diseases)

IT 170648-89-2P 189042-21-5P 189042-27-1P 189042-29-3P 189042-38-4P  
189042-40-8P 189042-43-1P 189042-47-5P 189042-57-7P 189042-75-9P  
189042-76-0P 189042-77-1P 189042-89-5P 189042-90-8P 189043-23-0P  
189043-25-2P 189043-30-9P 189043-78-5P 189044-06-2P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzimidazoles for the prevention and/or the treatment of bone diseases)

IT 189042-19-1P 189042-20-4P 189042-22-6P 189042-24-8P 189042-25-9P  
189042-26-0P 189042-28-2P 189042-30-6P 189042-31-7P 189042-32-8P  
189042-33-9P 189042-36-2P 189042-37-3P 189042-39-5P 189042-41-9P  
189042-42-0P 189042-44-2P 189042-45-3P 189042-46-4P 189042-48-6P  
189042-49-7P 189042-50-0P 189042-53-3P 189042-55-5P 189042-59-9P  
189042-61-3P 189042-63-5P 189042-64-6P 189042-66-8P 189042-67-9P  
189042-68-0P 189042-69-1P 189042-70-4P 189042-71-5P 189042-72-6P  
189042-73-7P 189042-74-8P 189042-78-2P 189042-79-3P 189042-80-6P  
189042-81-7P 189042-82-8P 189042-83-9P 189042-84-0P 189042-86-2P  
189042-87-3P 189042-91-9P 189042-92-0P 189042-93-1P 189042-94-2P  
189042-95-3P 189042-96-4P 189042-97-5P 189042-98-6P 189042-99-7P  
189043-00-3P 189043-01-4P 189043-02-5P 189043-03-6P 189043-04-7P  
189043-05-8P 189043-06-9P 189043-07-0P 189043-08-1P 189043-09-2P  
189043-10-5P 189043-11-6P 189043-13-8P 189043-15-0P 189043-17-2P  
189043-18-3P 189043-19-4P 189043-20-7P 189043-21-8P 189043-22-9P  
189043-24-1P 189043-26-3P 189043-28-5P 189043-31-0P 189043-32-1P  
189043-33-2P 189043-34-3P 189043-35-4P 189043-38-7P 189043-41-2P  
189043-43-4P 189043-45-6P 189043-46-7P 189043-47-8P 189043-48-9P  
189043-49-0P 189043-50-3P 189043-52-5P 189043-53-6P 189043-55-8P  
189043-56-9P 189043-57-0P 189043-58-1P 189043-59-2P 189043-60-5P  
189043-61-6P 189043-64-9P 189043-65-0P 189043-69-4P 189043-72-9P  
189043-73-0P 189043-74-1P 189043-77-4P 189043-81-0P 189043-82-1P  
189043-85-4P 189043-88-7P 189043-89-8P 189043-92-3P 189043-95-6P  
189043-98-9P 189043-99-0P 189044-02-8P 189044-04-0P 189044-07-3P

189044-08-4P 189044-09-5P 189044-10-8P 189044-11-9P 189044-12-0P  
 189044-13-1P 189044-14-2P 189044-15-3P 189044-16-4P 189044-17-5P  
 189044-18-6P 189044-19-7P 189044-20-0P 189044-21-1P 189044-22-2P

**189044-23-3P 189044-24-4P 189044-25-5P**

189044-26-6P 189044-27-7P 189044-28-8P 189044-29-9P 189044-31-3P  
 189044-32-4P 189044-33-5P 189044-34-6P 189044-35-7P 189044-37-9P  
 189044-39-1P **189044-40-4P** 189044-42-6P 189044-44-8P  
 189044-45-9P 189044-46-0P 189044-48-2P 189044-50-6P 189044-52-8P  
 189044-54-0P 189044-56-2P 189044-58-4P 189044-60-8P 189044-62-0P  
 189044-64-2P 189044-67-5P 189044-69-7P 189044-71-1P 189044-72-2P  
 189044-73-3P 189044-74-4P 189044-75-5P 189044-76-6P 189044-77-7P  
 189044-78-8P 189044-79-9P 189044-80-2P 189044-81-3P 189044-83-5P  
 189044-85-7P 189044-87-9P 189044-89-1P 189044-90-4P 189044-91-5P  
 189044-92-6P 189044-93-7P 189044-94-8P 189044-95-9P 189044-96-0P  
 189044-97-1P 189044-98-2P 189044-99-3P 189045-00-9P 189045-01-0P  
 189045-02-1P 189045-03-2P 189045-04-3P 189045-05-4P 189045-06-5P  
 189045-07-6P 189045-08-7P 189045-09-8P 189045-10-1P 189045-11-2P  
 189045-12-3P 189045-13-4P 189045-14-5P 189045-15-6P 189045-16-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of benzimidazoles for the prevention and/or the treatment of bone diseases)

IT 51-45-6, 4-(2-Aminoethyl)imidazole, reactions 60-56-0,  
 1-Methyl-2-mercaptoimidazole 61-54-1, 3-(2-Aminoethyl)indole 70-11-1,  
 Benzoylmethyl bromide 75-30-9, Isopropyl iodide 78-95-5 79-09-4,  
 Propanoic acid, reactions 79-14-1, reactions 87-63-8,  
 2-Chloro-6-methylaniline 88-17-5, 2-Trifluoromethylaniline 92-54-6,  
 1-Phenylpiperazine 96-33-3, Methyl acrylate 96-50-4, 2-Aminothiazole  
 98-10-2, Benzenesulfonamide 98-16-8, 3-Trifluoromethylaniline 99-98-9,  
 N,N-Dimethyl-1,4-phenylenediamine 100-11-8, 4-Nitrobenzyl bromide  
 100-39-0, Benzyl bromide 105-36-2, Ethyl bromoacetate 106-95-6, Allyl  
 bromide, reactions 108-33-8 108-55-4, Glutaric anhydride 109-01-3,  
 1-Methylpiperazine 109-70-6, 1-Bromo-3-chloropropane 109-85-3,  
 (2-Methoxyethyl)amine 110-91-8, Morpholine, reactions 111-42-2,  
 Bis(2-hydroxyethyl)amine, reactions 111-95-5 123-75-1, Pyrrolidine,  
 reactions 124-68-5, 2-Amino-1-hydroxy-2-methylpropane 137-00-8  
 156-87-6, (3-Hydroxypropyl)amine 288-32-4, Imidazole, reactions  
 455-14-1, 4-Trifluoromethylaniline 459-73-4, Glycine ethyl ester  
 461-72-3, Hydantoin 462-08-8, 3-Aminopyridine 504-24-5,  
 4-Aminopyridine 534-03-2 535-11-5, Ethyl 2-bromopropionate 536-90-3,  
 3-Methoxyaniline 541-41-3, Ethyl chloroformate 574-98-1,  
 2-Phthalimidoethyl bromide 589-10-6, 2-Bromoethyl phenyl ether  
 608-31-1, 2,6-Dichloroaniline 610-14-0, 2-Nitrobenzoyl chloride  
 617-88-9 617-89-0, 2-Aminomethylfuran 627-42-9, 2-Chloroethyl methyl  
 ether 824-94-2, 4-Methoxybenzyl chloride 870-46-2,  
 tert-Butoxycarbonylhydrazine 872-35-5, 2-Mercaptoimidazole 927-68-4,  
 2-Acetoxyethyl bromide 1003-03-8, Cyclopentylamine 1072-67-9,  
 3-Amino-5-methylisoxazole 1099-45-2, Ethyl (triphenylphosphoranylidene) a  
 cetate 1462-37-9, 2-Benzyloxyethyl bromide 1466-76-8 1772-01-6  
 1822-51-1, 4-Chloromethylpyridine hydrochloride 1989-53-3,  
 2,6-Dimethoxybenzoyl chloride 2417-90-5, 2-Cyanoethyl bromide  
 2620-50-0, 3,4-(Methylenedioxy)benzylamine 2687-25-4,  
 3-Methyl-1,2-phenylenediamine 2706-56-1, 2-(2-Aminoethyl)pyridine  
 2740-83-2 3132-64-7, 2,3-Epoxypropyl bromide 3260-89-7,  
 2-Chloro-6-methoxybenzoic acid 3647-69-6, 2-Morpholinoethyl chloride  
 hydrochloride 3694-52-8, 3-Nitro-1,2-phenylenediamine 3731-51-9,  
 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1,  
 4-Aminomethylpyridine 4005-51-0, 2-Amino-1,3,4-thiadiazole 4319-49-7,  
 4-Aminomorpholine 4331-29-7, 1H-Benzimidazol-4-amine 4556-23-4,  
 4-Mercaptopyridine 4597-87-9, 2-Methylaminopyridine 4659-45-4,  
 2,6-Dichlorobenzoyl chloride 4795-29-3, 2-Aminomethyltetrahydrofuran  
 4930-98-7, 2-Hydrazinopyridine 5292-43-3, tert-Butyl bromoacetate  
 5349-17-7 6482-24-2, 2-Methoxyethyl bromide 6628-77-9,  
 2-Methoxy-5-aminopyridine 6959-47-3, 2-Chloromethylpyridine  
 hydrochloride 6959-48-4, 3-Chloromethylpyridine hydrochloride

7250-67-1 10444-89-0, 2-Amino-5-trifluoromethyl-1,3,4-thiadiazole  
 13889-98-0, 1-Acetylpiperazine 14949-00-9, 5-Amino-1,3,4-thiadiazole-2-  
 sulfonamide 15159-40-7, Morpholinocarbonyl chloride 17694-68-7  
 20260-53-1, Nicotinoyl chloride hydrochloride 20850-43-5,  
 3,4-(Methylenedioxy)benzyl chloride 21900-37-8, 2,6-Dimethylbenzoyl  
 chloride 23468-31-7 25660-70-2 28188-41-2, 3-Cyanobenzyl bromide  
 32890-93-0, 2,6-Dichloro-3-methoxybenzoic acid 35573-93-4,  
 3,3-Diethoxypropyl chloride 35629-70-0, 2-Amino-4-methyloxazole  
 50868-73-0, 2-Methoxy-6-methylaniline 57731-17-6 58479-61-1,  
 tert-Butyldiphenylsilyl chloride 61063-11-4, Ethyl 2-amino-3-  
 nitrobenzoate 73902-41-7 74124-79-1, Disuccinimidyl carbonate  
 81156-68-5 119967-49-6 154714-19-9 155795-83-8 176750-70-2  
 189046-14-8 189046-15-9

RL: RCT (Reactant)

(prepn. of benzimidazoles for the prevention and/or the treatment of  
 bone diseases)

IT	6742-83-2P	6866-57-5P	14689-51-1P	37466-88-9P	74292-72-1P
	88218-10-4P	92824-08-3P	101236-92-4P	189045-17-8P	189045-18-9P
	189045-19-0P	189045-20-3P	189045-21-4P	189045-22-5P	189045-23-6P
	189045-24-7P	189045-25-8P	189045-26-9P	189045-27-0P	189045-28-1P
	189045-29-2P	189045-30-5P	189045-32-7P	189045-33-8P	189045-34-9P
	189045-35-0P	189045-37-2P	189045-39-4P	189045-41-8P	189045-43-0P
	189045-45-2P	189045-47-4P	189045-49-6P	189045-51-0P	189045-53-2P
	189045-54-3P	189045-55-4P	189045-56-5P	189045-57-6P	189045-58-7P
	189045-59-8P	189045-60-1P	189045-61-2P	189045-62-3P	189045-63-4P
	189045-64-5P	189045-65-6P	189045-66-7P	189045-67-8P	189045-68-9P
	189045-69-0P	189045-70-3P	189045-71-4P	189045-72-5P	189045-73-6P
	189045-74-7P	189045-75-8P	189045-76-9P	189045-77-0P	189045-78-1P
	189045-79-2P	189045-80-5P	189045-81-6P	189045-82-7P	189045-83-8P
	189045-84-9P	189045-85-0P	189045-86-1P	189045-87-2P	189045-88-3P
	189045-89-4P	189045-90-7P	189045-91-8P	189045-92-9P	189045-93-0P
	189045-94-1P	189045-95-2P	189045-96-3P	189045-97-4P	189045-98-5P
	189045-99-6P	189046-00-2P	189046-01-3P	189046-02-4P	189046-03-5P
	189046-04-6P	189046-05-7P	189046-06-8P	189046-07-9P	189046-08-0P
	189046-09-1P	189046-10-4P	189046-11-5P	189046-12-6P	189046-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of benzimidazoles for the prevention and/or the treatment of  
 bone diseases)



=> fil reg

FILE 'REGISTRY' ENTERED AT 10:44:48 ON 31 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 AUG 2000 HIGHEST RN 287950-86-1  
 DICTIONARY FILE UPDATES: 30 AUG 2000 HIGHEST RN 287950-86-1


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
 for details.

=> d sta que 163

L1 STR



NODE ATTRIBUTES:


NSPEC IS RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 7  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L3 23367 SEA FILE=REGISTRY SSS FUL L1  
 L6 STR



VAR G1=2/1/6/5

NODE ATTRIBUTES:

NSPEC IS RC AT 12  
 NSPEC IS RC AT 17  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 9

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L8 5 SEA FILE=REGISTRY SUB=L3 SSS FUL L6

L29 STR



REP G1=(1-20) 14

NODE ATTRIBUTES:

NSPEC IS RC AT 12

NSPEC IS RC AT 14

CONNECT IS X2 RC AT 7

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 9

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L32 7828 SEA FILE=REGISTRY ABB=ON PLU=ON L3 AND 333.401.35/RID  
 L34 891 SEA FILE=REGISTRY SUB=L32 SSS FUL L29  
 L35 873 SEA FILE=REGISTRY ABB=ON PLU=ON L34 NOT (CCS OR MNS OR PMS)/CI  
 L36 868 SEA FILE=REGISTRY ABB=ON PLU=ON L35 NOT L8  
 L37 114 SEA FILE=REGISTRY ABB=ON PLU=ON L36 AND CAOLD/LC  
 L38 25 SEA FILE=REGISTRY ABB=ON PLU=ON L37 AND 2/NR  
 L39 21 SEA FILE=REGISTRY ABB=ON PLU=ON L38 NOT (NITRO OR LEUCINE)  
 L41 139 SEA FILE=REGISTRY ABB=ON PLU=ON L36 AND 2/NR  
 L42 18 SEA FILE=REGISTRY ABB=ON PLU=ON L41 AND IDS/CI  
 L43 8 SEA FILE=REGISTRY ABB=ON PLU=ON L42 NOT (NITRO OR S/ELS)  
 L44 121 SEA FILE=REGISTRY ABB=ON PLU=ON L41 NOT L42  
 L45 106 SEA FILE=REGISTRY ABB=ON PLU=ON L44 NOT NITRO  
 L46 49 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND (VALINE OR SERINE OR OXIME OR IUM OR BETA OR ACETAMIDE OR HYDRAZIN? OR PROPENOIC OR DIOXOBUTYL OR SI/ELS)  
 L47 17 SEA FILE=REGISTRY ABB=ON PLU=ON L46 AND (C9H8CLN3O OR C13H17N3O OR C11H13N3O OR C10H11N3O OR C9H9N3O OR C13H17N3O2 OR C11H13N3O2 OR C13H13N3O OR C14H19N3O)  
 L48 11 SEA FILE=REGISTRY ABB=ON PLU=ON L47 NOT HYDROXY  
 L49 57 SEA FILE=REGISTRY ABB=ON PLU=ON L45 NOT L46  
 L50 12 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND (C11H14N4O OR C10H12N4O OR C10H12N4O OR C10H11N3O OR C11H13N3O OR C10H7CLF3N3O2 OR C12H14N3O OR C10H11BRN4O OR C13H17N3O OR C11H13N3O OR C10H9F3N4O)  
 L51 14 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND (C13H17N3O OR C9H9CLN4O OR C10H10BR2N4O OR C11H13N3O OR C10H9F3N4O OR C10H13N5O OR C11H14N4O OR C9H10N4O OR C12H15N3O OR C14H20N4O2)  
 L52 39 SEA FILE=REGISTRY ABB=ON PLU=ON (L39 OR L43 OR L48 OR L50 OR L51)  
 L53 6 SEA FILE=REGISTRY ABB=ON PLU=ON L52 AND (C10H7CLF3N3O2 OR C9H8CLN3O OR C9H9CLN4O OR C11H13N3O2)  
 L54 4 SEA FILE=REGISTRY ABB=ON PLU=ON 29233-40-7 OR 59769-23-2 OR 99857-16-6 OR 196617-68-2  
 L55 2 SEA FILE=REGISTRY ABB=ON PLU=ON L53 NOT L54  
 L56 37 SEA FILE=REGISTRY ABB=ON PLU=ON L52 NOT L55  
 L61 33 SEA FILE=REGISTRY ABB=ON PLU=ON L56 NOT L54

L62 1 SEA FILE=REGISTRY ABB=ON PLU=ON L54 AND C11H13N3O2  
L63 34 SEA FILE=REGISTRY ABB=ON PLU=ON (L61 OR L62)

=> d his l63-

(FILE 'REGISTRY' ENTERED AT 10:41:05 ON 31 AUG 2000)  
L63 34 S L61,L62  
DEL GSU20942E/A  
SAV L63 GSU20942E/A

FILE 'HCAOLD' ENTERED AT 10:44:07 ON 31 AUG 2000  
L64 5 S L63

FILE 'HCAPLUS' ENTERED AT 10:44:10 ON 31 AUG 2000  
L65 25 S L63


FILE 'USPATFULL' ENTERED AT 10:44:16 ON 31 AUG 2000  
L66 3 S L63

FILE 'REGISTRY' ENTERED AT 10:44:28 ON 31 AUG 2000

FILE 'REGISTRY' ENTERED AT 10:44:48 ON 31 AUG 2000

=> d ide can tot l63

L63 ANSWER 1 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 246163-29-1 REGISTRY  
CN 1H-Benzimidazole-1-acetic acid, 2-(trifluoromethyl)-, hydrazide (9CI) (CA  
INDEX NAME)  
FS 3D CONCORD  
MF C10 H9 F3 N4 O  
SR CA  
LC STN Files: CA, CAPLUS




2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:337255

REFERENCE 2: 131:286453


L63 ANSWER 2 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 193405-08-2 REGISTRY  
CN 1H-Benzimidazole-1-acetamide, 2-methyl-N-2-propynyl- (9CI) (CA  
INDEX NAME)  
FS 3D CONCORD  
MF C13 H13 N3 O  
SR CA  
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:149109

L63 ANSWER 3 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 152342-28-4 REGISTRY  
CN **1H-Benzimidazole-1-acetamide, N-butyl-2-methyl- (9CI)** (CA INDEX NAME)  
FS 3D CONCORD  
MF **C14 H19 N3 O**  
SR CA  
LC STN Files: CA, CAPLUS, CHEMINFORMRX




2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:77218

REFERENCE 2: 120:77217

L63 ANSWER 4 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 147621-92-9 REGISTRY  
CN Urea, N-[2-(6-methoxy-1H-benzimidazol-1-yl)ethyl]-N'-propyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C14 H20 N4 O2**  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254750

L63 ANSWER 5 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 131717-37-8 REGISTRY  
CN **1H-Benzimidazole-1-acetic acid, 2-ethyl-, hydrazide (9CI)** (CA INDEX NAME)  
FS 3D CONCORD  
MF **C11 H14 N4 O**

SR CA  
LC STN Files: CA, CAPLUS, CASREACT




3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:61463

REFERENCE 2: 128:22862

REFERENCE 3: 114:62011

L63 ANSWER 6 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 126993-64-4 REGISTRY  
CN **1H-Benzimidazole-1-acetamide, 2-methyl- (9CI)** (CA INDEX NAME)  
FS 3D CONCORD  
MF **C10 H11 N3 O**  
SR CA  
LC STN Files: CA, CAPLUS, CHEMINFORMRX




2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:77217

REFERENCE 2: 112:216795


L63 ANSWER 7 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 119771-77-6 REGISTRY  
CN **1-Benzimidazolepropionamide, ar-chloro- (6CI)** (CA INDEX NAME)  
MF C10 H10 Cl N3 O  
CI **IDS**  
SR CAOLD  
LC STN Files: CAOLD



D1 Cl

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 8 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 116857-94-4 REGISTRY  
 CN 1H-Benzimidazole-1-propanamide, 5,6-dimethyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C12 H15 N3 O**  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT  
 (\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:170325


L63 ANSWER 9 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 114255-58-2 REGISTRY  
 CN 1-Benzimidazoleacetamide, 5(or 6)-methyl- (6CI) (CA INDEX NAME)  
 MF C10 H11 N3 O  
 CI **IDS, COM**  
 SR CAOLD  
 LC STN Files: CAOLD



D1-Me

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 10 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 110493-05-5 REGISTRY  
 CN 1-Benzimidazoleacetamide, 5(or 6)-chloro-N-methyl- (6CI) (CA INDEX NAME)  
 MF C10 H10 Cl N3 O  
 CI **IDS, COM**  
 SR CAOLD  
 LC STN Files: CAOLD



D1 Cl

## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 11 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 110296-29-2 REGISTRY  
 CN 1-Benzimidazoleacetamide, 5(or 6)-chloro-N-ethyl- (6CI) (CA INDEX NAME)  
 MF C11 H12 Cl N3 O  
 CI **IDS**  
 SR CAOLD  
 LC STN Files: CAOLD



D1 Cl

## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 12 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 110296-26-9 REGISTRY  
 CN 1-Benzimidazolepropionamide, ar-methyl- (6CI) (CA INDEX NAME)  
 MF C11 H13 N3 O  
 CI **IDS**  
 SR CAOLD  
 LC STN Files: CAOLD



D1-Me

## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 13 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 110252-50-1 REGISTRY  
 CN 1-Benzimidazoleacetamide, N,5(or N,6)-dimethyl- (6CI) (CA INDEX NAME)  
 DR 110378-40-0  
 MF C11 H13 N3 O  
 CI **IDS, COM**  
 SR CAOLD  
 LC STN Files: CAOLD



D1-Me


## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 14 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 108520-67-8 REGISTRY  
 CN 1-Benzimidazoleacetamide, N-ethyl-5(or 6)-methyl- (6CI) (CA INDEX NAME)  
 MF C12 H15 N3 O  
 CI **IDS, COM**  
 SR CAOLD  
 LC STN Files: CAOLD



## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 15 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 107902-99-8 REGISTRY  
 CN 1H-Benzimidazole-1-acetic acid, 5,6-dimethyl-, hydrazide (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C11 H14 N4 O**  
 SR CA  
 LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, TOXLIT




## 1 REFERENCES IN FILE CA (1967 TO DATE)

## 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 106:168488

L63 ANSWER 16 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 105197-26-0 REGISTRY  
 CN 1H-Benzimidazole-1-propanoic acid, 4,6-dibromo-, hydrazide (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C10 H10 Br2 N4 O**  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT  
 (\*File contains numerically searchable property data)






1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:208805


L63 ANSWER 17 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 105197-25-9 REGISTRY  
CN 1H-Benzimidazole-1-propanoic acid, 6-bromo-, hydrazide (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C10 H11 Br N4 O**  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT  
(\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 105:208805

L63 ANSWER 18 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 103861-13-8 REGISTRY  
CN **1-Benzimidazoleacetamide, N,N-dimethyl- (6CI)** (CA INDEX NAME)  
FS 3D CONCORD  
MF **C11 H13 N3 O**  
SR CAOLD  
LC STN Files: BEILSTEIN\*, CAOLD  
(\*File contains numerically searchable property data)




1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 19 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 103857-64-3 REGISTRY  
CN 1-Benzimidazolepropionamide, .alpha.-methyl- (6CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C11 H13 N3 O**  
SR CAOLD  
LC STN Files: BEILSTEIN\*, CAOLD  
(\*File contains numerically searchable property data)




## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 20 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 103096-30-6 REGISTRY  
 CN **1-Benzimidazoleacetamide, N-methyl- (6CI)** (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C10 H11 N3 O**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)




## 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 21 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 100705-43-9 REGISTRY  
 CN **1-Benzimidazolepropionamide, 2-propyl- (6CI)** (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C13 H17 N3 O**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)




## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 22 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 100705-42-8 REGISTRY  
 CN **1-Benzimidazolepropionamide, 2-isopropyl- (6CI)** (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C13 H17 N3 O**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)




## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 23 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 100137-97-1 REGISTRY  
 CN 1-Benzimidazolepropionamide, .alpha.,2-dimethyl- (6CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C12 H15 N3 O**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)




## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 24 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN **99857-16-6** REGISTRY  
 CN 1-Benzimidazoleacetamide, N-2-hydroxyethyl- (6CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C11 H13 N3 O2**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)



## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L63 ANSWER 25 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 99856-89-0 REGISTRY  
 CN **1-Benzimidazoleacetamide, N-ethyl- (6CI)** (CA INDEX NAME)  
 FS 3D CONCORD  
 MF **C11 H13 N3 O**  
 SR CAOLD  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)



## 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L63 ANSWER 26 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 97968-89-3 REGISTRY  
 CN **1H-Benzimidazole-1-acetamide, N,N-diethyl- (9CI)** (CA INDEX NAME)  
 OTHER CA INDEX NAMES:


CN 1-Benzimidazoleacetamide, N,N-diethyl- (6CI)  
FS 3D CONCORD  
MF C13 H17 N3 O  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, SPECINFO  
(\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 103:104889

L63 ANSWER 27 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 97420-40-1 REGISTRY  
CN 1H-Benzimidazole-1-acetic acid, 2-methyl-, hydrazide (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C10 H12 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM



5 REFERENCES IN FILE CA (1967 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:61463


REFERENCE 2: 128:22862

REFERENCE 3: 120:77217

REFERENCE 4: 114:62011

REFERENCE 5: 103:53994

L63 ANSWER 28 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 97420-39-8 REGISTRY  
CN 1H-Benzimidazole-1-acetic acid, hydrazide (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C9 H10 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, CHEMCATS




3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:104994

REFERENCE 2: 125:315091

REFERENCE 3: 103:53994


L63 ANSWER 29 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 72550-35-7 REGISTRY  
CN Urea, [2-(6-amino-1H-benzimidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C10 H13 N5 O**  
LC STN Files: BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 92:58688

L63 ANSWER 30 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 59336-96-8 REGISTRY  
CN Urea, [2-(1H-benzimidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C10 H12 N4 O**  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, RTECS\*, TOXLIT  
(\*File contains numerically searchable property data)




2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:182452

REFERENCE 2: 85:5549

L63 ANSWER 31 OF 34 REGISTRY COPYRIGHT 2000 ACS  
RN 54980-94-8 REGISTRY  
CN **1H-Benzimidazole-1-acetamide, 2-ethyl-** (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C11 H13 N3 O**


LC STN Files: BEILSTEIN\*, CA, CAPLUS, CHEMCATS  
 (\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 82:140010

L63 ANSWER 32 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 54980-92-6 REGISTRY  
 CN **1H-Benzimidazole-1-acetamide (9CI)** (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN **1-Benzimidazoleacetamide (6CI)**  
 FS 3D CONCORD  
 MF **C9 H9 N3 O**  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CHEMCATS, TOXLIT  
 (\*File contains numerically searchable property data)




2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 129:293889

REFERENCE 2: 82:140010


L63 ANSWER 33 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 40508-01-8 REGISTRY  
 CN **1H-Benzimidazole-1-propanamide, 2-methyl-** (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN **1-Benzimidazolepropionamide, 2-methyl-** (6CI)  
 FS 3D CONCORD  
 MF **C11 H13 N3 O**  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CHEMCATS  
 (\*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 78:111212

L63 ANSWER 34 OF 34 REGISTRY COPYRIGHT 2000 ACS  
 RN 22492-17-7 REGISTRY  
 CN 1H-Benzimidazole-1-propanamide (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1-Benzimidazolepropionamide (6CI, 8CI)  
 FS 3D CONCORD  
 MF **C10 H11 N3 O**  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS  
 (\*File contains numerically searchable property data)



4 REFERENCES IN FILE CA (1967 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 109:170325

REFERENCE 2: 91:123671

REFERENCE 3: 78:111212

REFERENCE 4: 70:96715

=> fil hcaold

FILE 'HCAOLD' ENTERED AT 10:45:11 ON 31 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING  
 FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all tot 164

L64 ANSWER 1 OF 5 HCAOLD COPYRIGHT 2000 ACS  
 AN CA55:3560b CAOLD  
 TI synthesis of 4,5-bis(trifluoromethyl)benzimidazole  
 AU Fernandez Bolanos, J.; Overend, W. G.; Sykes, A.; Tatlow, J. C.; Wiseman, E. H.  
 IT 433-95-4 433-97-6 603-11-2 610-27-5 651-36-5 707-72-2  
 723-58-0 781-14-6 786-43-6 786-44-7 794-56-9 897-09-6  
 1978-06-9 1978-20-7 2741-57-3 2926-84-3 2965-07-3 3822-20-6

3855-52-5 3869-04-3 5466-84-2 **108520-67-8** 109820-14-6  
111057-80-8 114036-76-9 114036-77-0 114426-64-1 114637-66-0 114741-39-8  
117892-69-0 131252-36-3

L64 ANSWER 2 OF 5 HCAOLD COPYRIGHT 2000 ACS  
AN CA55:3559h CAOLD  
TI synthesis of derivs. of 5(or 6)-nitro-, 5(or 6)-chloro-, and 5(or 6)-methylbenzimidazole-N-acetic acids  
AU Inam-Ul-Haq  
IT 99849-20-4 108721-11-5 108726-34-7 **110252-50-1**  
**110296-29-2** 110378-41-1 **110493-05-5** 110941-10-1  
112072-28-3 **114255-58-2** 132488-49-4 133097-44-6

L64 ANSWER 3 OF 5 HCAOLD COPYRIGHT 2000 ACS  
AN CA53:20040g CAOLD  
TI N-alkyl-2-(1-benzimidazolyl)ethylamines  
AU Bell, S.; Foster, R.; Soutar, W. E. B.  
IT 5322-89-4 40516-96-9 87482-25-5 **97968-89-3** 99055-78-4  
99168-05-5 102550-06-1 102889-16-7 103046-81-7 **103096-30-6**  
103156-82-7 **103861-13-8**

L64 ANSWER 4 OF 5 HCAOLD COPYRIGHT 2000 ACS  
AN CA52:5725a CAOLD  
TI benzimidazole-N-acetic acid and its growth activity  
AU Cacace, Fulvio; Giuliano, R.; Inam-Ul-Haq  
IT 40332-16-9 **54980-92-6** 55175-50-3 **99856-89-0**  
**99857-16-6** 101284-71-3 **103096-30-6**

L64 ANSWER 5 OF 5 HCAOLD COPYRIGHT 2000 ACS  
AN CA52:2841h CAOLD  
TI 1-(.beta.-aminoalkyl)benzimidazoles  
AU Wheatley, William B.; Stiner, G. F.  
IT **22492-17-7** **40508-01-8** **100137-97-1**  
100318-11-4 **100705-42-8** **100705-43-9** 103394-45-2  
**103857-64-3** 107059-83-6 108014-39-7 108040-45-5  
**110296-26-9** 115861-34-2 116843-12-0 116867-39-1  
**119771-77-6**

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:45:17 ON 31 AUG 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 31 Aug 2000 VOL 133 ISS 9  
FILE LAST UPDATED: 30 Aug 2000 (20000830/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.


Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.



=> d 165 bib abs hitrn tot

L65 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 2000:272503 HCAPLUS  
 DN 133:104994  
 TI Synthesis of some (6-nitrobenzimidazol-1-yl)acetyl hydrazones  
 AU Liu, Suyan; Gao, Yuan; Xu, Pengfei; Zhang, Ziyi; Li, Hulin  
 CS College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, Peop. Rep. China  
 SO Lanzhou Daxue Xuebao, Ziran Kexueban (2000), 36(1), 65-70  
 CODEN: LCTHAF; ISSN: 0455-2059  
 PB Lanzhou Daxue  
 DT Journal  
 LA Chinese  
 AB Eight arom. hydrazones were prepd. from (benzimidazol-1-yl)acetic acid or its deriv. by substituting with hydrazine hydrate, and condensing with various aryl aldehydes (p-dimethylaminobenzaldehyde, m-nitrobenzaldehyde, o-chlorobenzaldehyde, p-chlorobenzaldehyde, o-hydroxybenzaldehyde), acetone, and acetylferrocene, etc in a mixed soln. of abs. ethanol and DMF for 48 h. The compds. were identified by elemental analyses, IR, <sup>1</sup>H NMR, and MS.  
 IT **97420-39-8P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of nitrobenzimidazolylacetyl hydrazones)

L65 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:584161 HCAPLUS  
 DN 131:337255  
 TI Synthesis of 1-aryl-4-[1'-N-.beta.-D-glycopyranosyl]thiosemicarbazides  
 AU Yu, Jianxin; Liu, Fangming; Li, Yanping; Cheng, Liang; Fan, Xin; Liu, Yuting  
 CS Department of Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China  
 SO Yingyong Huaxue (1999), 16(4), 41-46  
 CODEN: YIHUED; ISSN: 1000-0518  
 PB Yingyong Huaxue Bianji Weiyuanhui  
 DT Journal  
 LA Chinese  
 GI



AB Title compds. I (X = .beta.-Q; R = OH, OAc; R1 = H, CH<sub>2</sub>OAc; Ar = C<sub>6</sub>H<sub>5</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>, 2-MeOC<sub>6</sub>H<sub>4</sub>, 2-HOC<sub>6</sub>H<sub>4</sub>, 4-pyridyl, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, etc.) were prepd. from I (X = .alpha.-Br; R, R1, Ar as above), with I (X = .beta.-NCS; R, R1, Ar as above) as intermediates, in 95% EtOH under reflux.

IT **246163-29-1**

RL: RCT (Reactant)  
 (synthesis of 1-aro-yl-4-[1'-N-.beta.-D-glycopyranosyl]thiosemicarbazide  
 s)

L65 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:562346 HCAPLUS

DN 131:286453

TI Synthesis of heterocyclic compounds from 2-trifluoromethylbenzimidazol-1-  
 acetic acid hydrazide

AU Liu, Fang-Ming; Lu, Wen-Jie; Zhang, Zhen-Fang; Wang, Bao-Lei; Liu, Yu-Ting

CS Dep. Chem., Xinjiang Univ., Ulumuqi, 830046, Peop. Rep. China

SO Gaodeng Xuexiao Huaxue Xuebao (1999), 20(8), 1242-1247



CODEN: KTHPDM; ISSN: 0251-0790

PB Gaodeng Jiaoyu Chubanshe

DT Journal

LA Chinese

GI



AB A series of new 1,3,4-oxadiazoline and 1,2,4-triazolo[3,4-  
 b][1,3,4]thiadiazole derivs. I (Ar = heterocyclic) were prepd. from  
 2-trifluoromethylbenzimidazol-1-acetic acid hydrazide. The title compd.  
 II was prepd. and identified by IR, 1H NMR, MS and elementary anal.

IT **246163-29-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of heterocyclic compds. from 2-trifluoromethylbenzimidazol-1-  
 acetic acid hydrazide)

L65 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1998:672469 HCAPLUS

DN 129:293889

TI Pharmaceutical composition containing a phosphorylamide and an antibiotic

IN Oi, Satoru; Inatomi, Nobuhiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842347	A1	19981001	WO 1998-JP1267	19980324

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW,  
 HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN,

MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US,  
UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
GA, GN, ML, MR, NE, SN, TD, TG

AU 9864222 A1 19981020 AU 1998-64222 19980324  
JP 10324632 A2 19981208 JP 1998-76346 19980324

PRAI JP 1997-71391 19970325  
WO 1998-JP1267 19980324

OS MARPAT 129:293889

AB A pharmaceutical compn. comprising RP(O)(NH<sub>2</sub>)<sub>2</sub>, wherein R represents an amino group which may be substituted, or a salt thereof, and an antibiotic, possesses excellent antibacterial activity, esp. potent antibacterial activity against Helicobacter bacteria such as H. pylori, and is useful for prevention or treatment of digestive diseases caused by Helicobacter bacteria, solely or in combination with an antacid and/or an acid secretion inhibitor. Of many compds. prepd. was N-(diaminophosphinyl)-2-thiophenecarboxamide. Ninety-nine compds. were tested for inhibitory effect against H. pylori-derived urease. Pharmaceutical formulations were also given.

IT **54980-92-6P**, 1H-Benzimidazole-1-acetamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(pharmaceutical compn. contg. a phosphorylamide and an antibiotic for treatment of Helicobacter infection)

L65 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:730159 HCAPLUS

DN 128:61463

TI Synthesis and antimicrobial testing of 4H-1,2,4-triazole, 1,2,4-triazolo[3,4-b][1,3,4]thiadiazole, and 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine derivatives of 1H-benzimidazole

AU Habib, Nargues S.; Soliman, R.; Ashour, F. A.; El-Taiebi, M.

CS Fac. Pharmacy, Univ. Alexandria, Alexandria, Egypt

SO Pharmazie (1997), 52(11), 844-847

CODEN: PHARAT; ISSN: 0031-7144

PB Govi-Verlag Pharmazeutischer Verlag

DT Journal

LA English

OS CASREACT 128:61463

AB Three novel series of benzimidazole derivs. namely 6-substituted 3-[1-(2-alkyl-1H-benzimidazolyl)methyl]-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles, 6-substituted 3-[1-(2-alkyl-1H-benzimidazolyl)methyl]-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines, and 6-thioxo-3-[1-(2-alkyl-1H-benzimidazolyl)methyl]-5,6-dihydro-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles were prepd. by cyclization of 1-[(4-amino-5-mercapto-4H-1,2,4-triazol-3-yl)methyl]-2-alkyl-1H-benzimidazoles as the key intermediates. Furthermore, 1-[(4-arylideneamino-5-mercapto-4H-1,2,4-triazol-3-yl)-methyl]-2-alkyl-1H-benzimidazoles were prepd., and some of them were cyclized to 6-substituted 3-[1-(2-alkyl-1H-benzimidazolyl)methyl]-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles using SO<sub>2</sub>Cl<sub>2</sub>. The prepd. compds. were tested for antimicrobial activity in vitro and showed moderate activity.

IT **97420-40-1 131717-37-8**

RL: RCT (Reactant)

(prepn. and antimicrobial activity of triazole, triazolothiadiazole, and triazolothiadiazine derivs. of benzimidazole)

L65 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:687429 HCAPLUS

DN 128:22862

TI Synthesis and antimicrobial testing of novel oxadiazolylbenzimidazole derivatives

AU Habib, Nargues Samuel; Soliman, R.; Ashour, F. A.; El-Taiebi, M.

CS Faculty Pharmacy, University Alexandria, Alexandria, Egypt

SO Pharmazie (1997), 52(10), 746-749


CODEN: PHARAT; ISSN: 0031-7144

PB Govi-Verlag Pharmazeutischer Verlag  
DT Journal  
LA English  
OS CASREACT 128:22862  
AB Three novel series of oxadiazolylbenzimidazoles were prep'd., namely  
1-[(2-alkyl/aralkylthio-1,3,4-oxadiazol-5-yl)methyl]-,  
1-[(3-aminomethyl-2-thioxo-2,3-dihydro-1,3,4-oxadiazol-5-yl)methyl]-, and  
1-[(2-amino-1,3,4-oxadiazol-5-yl)methyl]-2-alkyl-1H-benzimidazoles. Some  
of the compds. showed weak antimicrobial activity.  
IT **97420-40-1 131717-37-8**  
RL: RCT (Reactant)  
(prepn. of oxadiazolylbenzimidazoles with weak antimicrobial activity)

L65 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
AN 1997:532510 HCAPLUS  
DN 127:149109  
TI Azino-Fused Benzimidazolium Salts as DNA Intercalating Agents. 2.  
AU Pastor, Joaquin; Siro, Jorge G.; Garcia-Navio, Jose L.; Vaquero, Juan J.;  
Alvarez-Builla, Julio; Gago, Federico; de Pascual-Teresa, Beatriz; Pastor,  
Manuel; Rodrigo, M. Melia  
CS Departamento de Quimica Organica Departamento de Quimica-Fisica and  
Departamento de Farmacologia, Universidad de Alcala, Madrid, 28871, Spain  
SO J. Org. Chem. (1997), 62(16), 5476-5483  
CODEN: JOCEAH; ISSN: 0022-3263  
PB American Chemical Society  
DT Journal  
LA English  
AB The synthesis of new pyrido[1,2-a]- and pyridazino[1,6-a]benzimidazolium  
salts by basic condensation of 1,3-disubstituted 2-alkylbenzimidazolium  
salts and 1,2-diketones and subsequent chem. transformations is described.  
The DNA-binding properties were exam'd. by UV-vis spectroscopy,  
viscosimetric detn., and mol. modeling techniques. The presence of a flat  
polycyclic hydrocarbon moiety such as a naphthalene-1,8-diyl or a  
biphenyl-o,o'-diyl, fused to the cationic heterocycle, appears to enhance  
the interaction with DNA. Variation of the substituents on the  
indole-like N will allow us to build up a new series of bis-salts with  
bis-intercalating properties.  
IT **193405-08-2**  
RL: RCT (Reactant)  
(prepn. of azino-fused benzimidazolium salts as DNA intercalating  
agents)

L65 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
AN 1996:570261 HCAPLUS  
DN 125:315091  
TI New metal complexes derived from 1-N-(benzimidazole-1-acetyl)-4-phenyl-3-  
thiosemicarbazide  
AU Xu, Zhuguo; Xu, Pengfei; Wu, Shaozu  
CS Lanzhou Med. Coll., Lanzhou, 730000, Peop. Rep. China  
SO Hecheng Huaxue (1996), 4(2), 137-140  
CODEN: HEHUE2; ISSN: 1005-1511  
DT Journal  
LA Chinese  
AB The synthesis of Mn(II), Cu(II), Co(II), Zn(II), Cd(II), Ni(II) and  
UO2(II) complexes of new ligand 1-N-(benzimidazole-1-acetyl)-4-phenyl-3-  
thiosemicarbazide (BPMS) was reported. These compds. were characterized  
by elemental anal., IR, 1H NMR and thermoanal. IR spectra showed that the  
complex was a tetradentate coordination compd. involving a carbonyl and a  
thiocarbonyl group connected with the adjacent nitrogen atoms (C:N groups)  
with each ligand binding to two metal centers. The resultant complexes  
are proposed to be a polymeric structure that repeats through consecutive  
ligand-metal linkage.  
IT **97420-39-8P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction with Ph isothiocyanate)


L65 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1994:77218 HCAPLUS  
 DN 120:77218  
 TI Investigation in the imidazole series. 94. Synthesis of  
 pyrrolo[1,2-a]benzimidazolyl-4-acetic acid derivatives  
 AU Kochergin, P. M.; Paley, R. M.; Chernyak, S. A.  
 CS Tsentr. Khim. Lekar. Sredstv, Moscow, 119815, Russia  
 SO Khim. Geterotsikl. Soedin. (1993), (5), 659-63  
 CODEN: KGSSAQ; ISSN: 0132-6244  
 DT Journal  
 LA Russian  
 OS CASREACT 120:77218  
 GI



AB Quaternization of benzimidazolyl-4-acetic acid derivs. I [R = OH, alkoxy, (substituted)amino, R1 = H, Ph, Me] with BrCH2COR2 [R2 = Me, (un)substituted Ph] afforded benzimidazolium derivs. II (in up to 95% yield); basic cyclization of II afforded the title compds. III in up to 87% yield. III (R = amino) amides were prepd. via 3 methods: cyclization of the corresponding II amide; cyclization/amidation of the corresponding II ester with the desired amine; and amidation of III ester with the desired amine.

IT **152342-28-4**  
 RL: RCT (Reactant)  
 (quaternization of, with bromomethyl ketone)

L65 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1994:77217 HCAPLUS  
 DN 120:77217  
 TI Investigation in the imidazole series. 93. Synthesis of  
 benzimidazole-1-acetic acid derivatives  
 AU Kochergin, P. M.; Paley, R. M.; Chernyak, S. A.  
 CS Tsentr. Khim. Lekar. Sredstv, Moscow, 119815, Russia  
 SO Khim. Geterotsikl. Soedin. (1993), (5), 656-8  
 CODEN: KGSSAQ; ISSN: 0132-6244  
 DT Journal  
 LA Russian  
 GI



AB Benzimidazole-1-acetates and their 2-alkyl(aralkyl) substituted derivs. I (R = H, Me, Et, PhCH2, R1 = Me, Et) were easily obtained in 70-97% yields

by reaction of benzimidazoles with Cl(Br)CH<sub>2</sub>CO<sub>2</sub>R<sub>1</sub> in DMF contg anhyd. K<sub>2</sub>CO<sub>3</sub>. The corresponding amides were obtained in 53-99 yields by reactions with R<sub>2</sub>NH<sub>2</sub> (R<sub>2</sub> = H, Bu, cyclobutyl, NH<sub>2</sub>).

IT **97420-40-1P 126993-64-4P 152342-28-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

L65 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1993:254750 HCAPLUS

DN 118:254750

TI Arylethylamine derivatives, processes for their preparation and pharmaceutical uses

IN Lesieur, Daniel; Yous, Said; Depreux, Patrick; Andrieux, Jean; Adam, Gerard; Caignard, Daniel Henri; Guardiola, Beatrice

PA ADIR et Cie., Fr.

SO Eur. Pat. Appl., 32 pp.


CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 527687	A2	19930217	EP 1992-402279	19920813
	EP 527687	A3	19930310		
	EP 527687	B1	19951122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2680366	A1	19930219	FR 1991-10261	19910813
	FR 2680366	B1	19950120		
	CA 2075876	AA	19930214	CA 1992-2075876	19920812
	AU 9220950	A1	19930218	AU 1992-20950	19920812
	AU 649864	B2	19940602		
	US 5276051	A	19940104	US 1992-931574	19920812
	ZA 9206093	A	19931115	ZA 1992-6093	19920813
	JP 06199784	A2	19940719	JP 1992-258801	19920813
	JP 2521396	B2	19960807		
	AT 130604	E	19951215	AT 1992-402279	19920813
	ES 2083123	T3	19960401	ES 1992-402279	19920813
	US 5308866	A	19940503	US 1993-93279	19930719
	US 5380750	A	19950110	US 1993-93769	19930719
PRAI	FR 1991-10261		19910813		
	US 1992-931574		19920812		
OS	MARPAT 118:254750				
GI					



AB Arylethylamines Ar'CH<sub>2</sub>CH<sub>2</sub>NR<sub>1</sub>R<sub>2</sub> are prepd. in which Ar' = variously substituted heterocycles, including indol-3-yl, benzo[b]thiophen-3-yl, benzimidazol-1-yl, benzo[b]furan-3-yl, 1,2-benzisoxazol-3-yl, 1,2-benzisothiazol-3-yl, or indazol-3-yl derivs., R<sub>1</sub> = COR<sub>7</sub> [R<sub>7</sub> = (un)substituted cycloalkyl or cycloalkyl-(C1-4)alkyl, CF<sub>3</sub>, or R<sub>7</sub> = linear or branched halo-(un)substituted C1-6 alkyl for certain Ar'], or R<sub>1</sub> = CONHR<sub>8</sub> or CSNHR<sub>8</sub> [R<sub>8</sub> = linear or branched C1-6 alkyl, (un)substituted cycloalkyl or cycloalkyl-(C1-4)alkyl, (un)substituted Ph or aryl-(C1-3)alkyl], or R<sub>1</sub> = CO(CH<sub>2</sub>)<sub>n</sub>E<sub>1</sub> [n = 1-3, E<sub>1</sub> = morpholino, piperazine (un)substituted with (CH<sub>2</sub>)<sub>n</sub>E<sub>2</sub>, where n = 1-4, E<sub>2</sub> = (un)substituted Ph or naphthyl], and R<sub>2</sub> = H, linear or branched C1-6

alkyl. Thus, reaction of 5-methoxytryptamine with cyclopropanecarboxylic acid chloride in H<sub>2</sub>O/CHCl<sub>3</sub> in the presence of K<sub>2</sub>CO<sub>3</sub> for 30 min. afforded example title compd. I in 80.5% yield. The aryylethylamines were tested and are claimed for a variety of pharmaceutical applications. These studies and applications include binding to melatonin receptors, treatment of ischemia microcirculation, stimulation of the immune response, ovulation inhibition, use as anxiolytics, antipsychotics, analgesics, neoplasm inhibitors of selected cancers, for treatment of skin disorders, e.g., psoriasis, acne, and seborrhea, and in veterinary skin disorder. A tablet formulation comprising N-[2-(5-methoxyindol-3-yl)ethyl]-N'propylurea is given.

IT **147621-92-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and pharmaceutical applications of)

L65 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1991:62011 HCAPLUS

DN 114:62011

TI Synthesis of benzimidazole derivatives as potential antimicrobial agents

AU Habib, Nargues Samuel; Abdel-Hamid, Soad; El-Hawash, M.

CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt


SO Farmaco (1989), 44(12), 1225-32

CODEN: FRMCE8

DT Journal

LA English

GI






AB Three novel series of title compds. were prepd. from alkylbenzimidazolacetic acid hydrazides I (R = Me, Et) and R<sub>1</sub>NCS (R<sub>1</sub> = Bu, Ph, cyclohexyl, PhCH<sub>2</sub>) namely; alkylthioxotriazolylmethylbenzimidazoles II, aminothiadiazolylmethylbenzimidazoles III, and 2-alkyl[(thiazolinylidene)hydrazinocarbonyl]methylbenzimidazoles IV (R<sub>2</sub> = H, Cl). Antimicrobial testing of prepd. compds. as well as of the key intermediate thiosemicarbazides showed most of the compds. were active against Staphylococcus aureus, Escherichia coli, and Candida albicans.

IT **97420-40-1 131717-37-8**

RL: RCT (Reactant)

(addn. reaction of, with isothiocyanates and bactericidal and fungicidal activity of)

L65 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1990:216795 HCAPLUS  
 DN 112:216795  
 TI Aminomethylamides of N-benzazolylacetic acids  
 AU Domagalina, Eugenia; Bien, Irena; Zawisza, Pawel  
 CS Dep. Chem. Drugs, Sch. Med., Lublin, 20-022, Pol.  
 SO Acta Pol. Pharm. (1989), 46(2), 114-18  
 CODEN: APPHAX; ISSN: 0001-6837  
 DT Journal  
 LA Polish  
 GI



AB In the reaction with  $\text{BrCH}_2\text{CO}_2\text{Et}$ , a benzazole was converted into the N-ethoxycarbonylmethyl deriv., which was subject to ammonolysis to yield the N-carbamoylmethyl deriv. This was finally treated with  $\text{CH}_2\text{O}$  and morpholine or piperidine. Thus were prepd.: I ( $\text{R} = \text{H}$ , 5- and 6-Cl), II, III, and IV (all with  $\text{X} = \text{O}$ ,  $\text{CH}_2$ ). In preliminary pharmacol. tests, the N-carbamoylmethyl derivs. revealed moderate analgesic, myolytic, and depressant activity in mice.

IT **126993-64-4P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and aminomethylation of)

L65 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1988:570325 HCAPLUS  
 DN 109:170325  
 TI Synthesis and spectroscopic properties of N-azolypropenamides  
 AU De la Cruz, Angeles; Elguero, Jose; Goya, Pilar; Martinez, Ana  
 CS Inst. Quim. Med., CSIC, Madrid, 28006, Spain  
 SO J. Heterocycl. Chem. (1988), 25(1), 225-9  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 109:170325  
 GI





AB Fourteen N-azobenzylpropanamides, e.g. I and II, have been prep'd. by Michael addn. of azoles with acrylamide. The compds. have been fully characterized by IR and <sup>1</sup>H and <sup>13</sup>C-NMR. The isolated compds. are the most stable derivs.; kinetic compds. were obsd. but could not be isolated.

IT **22492-17-7P**, 1H-Benzimidazole-1-propanamide **116857-94-4P**

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and spectra of)

L65 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1987:168488 HCAPLUS

DN 106:168488

TI Identification of 2-benzimidazolylurea as a new antimitotic compound based on cross resistance studies with nocodazole resistant mutants of CHO cells

AU Gupta, Radhey S.

CS Dep. Biochem., McMaster Univ., Hamilton, ON, L8N 3Z5, Can.

SO Biochem. Biophys. Res. Commun. (1987), 143(1), 225-32

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

AB The cross-resistance patterns of a set of nocodazole [31430-18-9]-resistant (NocR) and podophyllotoxin [518-28-5]-resistant (PodR) mutants of Chinese hamster ovary cells, which exhibit highly-specific cross-resistance toward compds. that show nocodazole-like antimitotic activity, towards a large no. of benzimidazole derivs. was examd. Of the various compds. examd., the NocR and the PodR mutants were found to exhibit increased cross-resistance towards only 2-benzimidazolylurea [24370-25-0], indicating that this compd. may possess similar biol. activity as nocodazole. The nocodazole-like antimitotic activity of 2-benzimidazolylurea was confirmed by its ability to block cells in mitosis, and by its competition of [<sup>3</sup>H]podophyllotoxin binding to microtubule proteins in cell exts. The nocodazole-like behavior of 2-benzimidazolylurea and lack of similar activity in other benzimidazole derivs. examd., provides valuable information regarding structural features that are required for this type of biol. activity.

IT **107902-99-8**

RL: BAC (Biological activity or effector, except adverse); BIOL

(Biological study)

(antimitotic activity of, in nocodazole- and podophyllotoxin-resistant cells)

L65 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1986:608805 HCAPLUS

DN 105:208805

TI Cyanoethylation of benzimidazoles: synthesis and biological activities of some new 1-(.beta.-cyanoethyl)benzimidazoles and their derivatives

AU Kumar, B. Vijaya; Reddy, V. Malla

CS Univ. Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009, India

SO Indian J. Chem., Sect. B (1985), 24B(10), 1098-101


CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 105:208805

GI



AB 1-(.beta.-Cyanoethyl)benzimidazoles I (R = CH<sub>2</sub>CH<sub>2</sub>CN; R<sub>1</sub> = NO<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H; R<sub>1</sub> = R<sub>2</sub> = R<sub>4</sub> = H, R<sub>3</sub> = Br; R<sub>1</sub> = R<sub>3</sub> = Br, R<sub>2</sub> = R<sub>4</sub> = H) were prepd. by the Michael addn. of acrylonitrile on benzimidazoles I (R = H). Their acid hydrolysis furnished the corresponding benzimidazolylpropionic acids I (R = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H) which were esterified to the ethyl esters. The benzimidazolylpropionic acid hydrazides I (R = CH<sub>2</sub>CH<sub>2</sub>CONHNH<sub>2</sub>) were obtained in quant. yields by the action of N<sub>2</sub>H<sub>4</sub> on the Et esters. The acute toxicity and antifungal, analgesic and antiinflammatory activities of I (R = CH<sub>2</sub>CH<sub>2</sub>CN, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H) were detd.

IT **105197-25-9P 105197-26-0P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and antifungal activity of)

L65 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1985:504889 HCAPLUS

DN 103:104889

TI Homolytic substitution and carbenoidic reactions in the preparation of benzimidazole derivatives of pharmaceutical interest: synthesis and properties of (2-cycloalkyl-1-benzimidazolyl)-N,N-diethylacetamides

AU Pellicciari, Roberto; Fringuelli, Renata; Natalini, Benedetto; Brucato, Leonardo; Contessa, Anna Rita

CS Ist. Chim. Farm. Tec. Farm., Univ. Studi Perugia, Perugia, I-06100, Italy

SO Arch. Pharm. (Weinheim, Ger.) (1985), 318(5), 393-9

CODEN: ARPMAS; ISSN: 0365-6233

DT Journal

LA English

OS CASREACT 103:104889

GI



AB The title compds. I (R = cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) were prepd. by the homolytic cycloalkylation of benzimidazole with RCO<sub>2</sub>H and the N-alkylation of benzimidazole by the ethoxycarbonylcarbenoid generated by the copper bronze-catalyzed decompn. of Et diazoacetate.

IT **97968-89-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and antispasmodic activity of)

L65 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2000 ACS


AN 1985:453994 HCAPLUS

DN 103:53994

TI Synthesis of N-benzoxazolinone, N-benzothiazolinone and N-benzimidazole arylidene hydrazides

AU Domagalina, Eugenia; Bien, Irena; Gaj, Barbara; Zawisza, Pawel

CS Inst. Anal. Technol. Farm., Akad. Med., Lublin, Pol.  
 SO Ann. Univ. Mariae Curie-Sklodowska, Sect. D (1984), Volume Date 1982, 37,  
 177-82  
 CODEN: AUMKAS; ISSN: 0066-2240  
 DT Journal  
 LA Polish  
 GI



AB Twenty title hydrazides (e.g., I, and II) were prepd. by treating the appropriate heterocycle with ClCH<sub>2</sub>CO<sub>2</sub>Et, followed by hydrazinolysis and treatment with an arom. or hetaryl aldehyde. The compds. were prepd. as potential bactericides and anthelmintics (no data).

IT **97420-39-8P 97420-40-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction with aldehydes)

L65 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1980:58688 HCAPLUS

DN 92:58688

TI Synthesis and pharmacological study of some derivatives of benzimidazole.  
 VIII. Benzimidazole derivatives of urea

AU Mukhina, N. A.; Shkrabova, L. V.; Romanova, T. V.; Pechenina, V. M.;  
 Kazakova, V. P.; Pashinskii, V. G.

CS Nauchno-Issled. Khim.-Farm. Inst., Novokuznetsk, USSR


SO Khim.-Farm. Zh. (1979), 13(10), 39-44

CODEN: KHFZAN; ISSN: 0023-1134

DT Journal

LA Russian

GI



AB Reaction of aminobenzimidazole I (R<sub>2</sub> = 5- or 6-NH<sub>2</sub>; R = R<sub>4</sub> = H; R = H, R<sub>1</sub> = Me, Et; R = Me, benzyl, CH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>NHCONH<sub>2</sub>, R<sub>1</sub> = H) with O<sub>2</sub>NNHCONH<sub>2</sub> and NaCNO gave 42-95% I (R<sub>2</sub> = 5- or 6-NHCONH<sub>2</sub>). II (R = Et, PhOCH<sub>2</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>) and III (R = EtCO, R<sub>1</sub> = Et; R = PhOCH<sub>2</sub>CO, R<sub>1</sub> = EtOCH<sub>2</sub>; R = EtCONHCO, R<sub>1</sub> = Et; R = PhOCH<sub>2</sub>CONHCO, R<sub>1</sub> = PhOCH<sub>2</sub>; R = 4-MeOC<sub>6</sub>H<sub>4</sub>CONHCO, R<sub>1</sub>

= 4-MeOC<sub>6</sub>H<sub>4</sub>) were prepd. by acylation. I (R<sub>2</sub> = 5- or 6-H<sub>2</sub>NCONH; R<sub>1</sub> = H, R = H, benzyl), II (R = 4-MeOC<sub>6</sub>H<sub>4</sub>) and III (R = EtCO, R<sub>1</sub> = Et; R = PhOCH<sub>2</sub>CONHCO, R<sub>1</sub> = PhOCH<sub>2</sub>) have diuretic activity and increase diuresis by 2-4 times relative to the control. II (R = Et, PhOCH<sub>2</sub>) have an antidiuretic effect.

IT **72550-35-7**

RL: RCT (Reactant)  
(reaction of, with nitrourea)

L65 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1979:523671 HCAPLUS

DN 91:123671

TI Synthesis in the benzimidazole series. Synthesis of benzimidazole N-.beta.-ethyl carboxylic acid and 2-methyl benzimidazole N-.beta.-ethyl carboxylic acid

AU Alam, M. N.

CS Chem. Div., BCSIR Lab., Chittagong, Bangladesh


SO Bangladesh Pharm. J. (1978), 7(3), 22-4

CODEN: BPJLAQ; ISSN: 0301-4606

DT Journal

LA English

GI



AB Benzimidazole was treated with H<sub>2</sub>C:CHCN to give the benzimidazole I (R = CN), which was hydrolyzed and the I (R = CONH<sub>2</sub>) further hydrolyzed to give I (R = CO<sub>2</sub>H).

IT **22492-17-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and hydrolysis of)

L65 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1978:182452 HCAPLUS

DN 88:182452

TI Diuretic activity of benzimidazole derivatives of urea

AU Pashinskii, V. G.; Romanova, T. V.; Mukhina, N. A.; Shkrabova, L. V.; Tetenchuk, K. P.

CS Lab. Biol. Kontrolya, Novokuz. Nauchno-Issled. Khim.-Farm. Inst., Novokuznets, USSR


SO Farmakol. Toksikol. (Moscow) (1978), 41(2), 196-9

CODEN: FATOAO; ISSN: 0014-8318

DT Journal

LA Russian

GI



AB Six of 16 benzimidazole derivs. of urea (I) had diuretic activity in rats whereas 6 had antidiuretic activity and 4 had no activity. Benzimidazole-1-ethylurea [59336-96-8] had the greatest diuretic effect. The diuretic activity of I depended on the nature of the acyl radicals: compds. with an odd no. of C atoms had expressed diuretic

activity, whereas those with an even no. of C atoms were practically inactive. Diuretic properties of compds. contg. nitro groups had little or no activity. The valeric acid deriv. [59337-02-9] had moderate diuretic activity, whereas the isovaleric acid deriv. [66473-25-4] had antidiuretic properties.

IT **59336-96-8**

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(diuretic activity of, structure in relation to)

L65 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1976:405549 HCAPLUS

DN 85:5549

TI Synthesis and pharmacological studies of some benzimidazole derivatives. VI. Benzimidazole derivatives of urea

AU Shkrabova, L. V.; Mukhina, N. A.; Kurilenko, V. M.; Gilev, A. P.; Basova, L. P.; Motovilova, V. G.; Romanova, T. V.; Pashinskii, V. G.

CS Novokuz. Nauchno-Issled. Khim.-Farm. Inst., Novokuznetsk, USSR


SO Khim.-Farm. Zh. (1976), 10(2), 49-53

CODEN: KHFZAN

DT Journal

LA Russian

GI



AB (Benzimidazolylethyl)ureas I (R = H, 5-, 6-NO<sub>2</sub>, R<sub>1</sub> = C1-5 alkyl, Ph, PhCH<sub>2</sub>, PhCH:CH, p-MeOC<sub>6</sub>H<sub>4</sub>, o-BrC<sub>6</sub>H<sub>4</sub>), useful as analgesics, muscle relaxants, and diuretics, were obtained in 84-99% yields by acylation of the corresponding (benzimidazolylethyl)urea with RCOCl.

IT **59336-96-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and acylation of)

L65 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1975:140010 HCAPLUS

DN 82:140010

TI Reactions of cyanomethylbenzimidazoles. I. Synthesis of 1- and 2-cyanomethylbenzimidazoles and some of their derivatives

AU Sawlewicz, Jozef; Milczarska, Barbara

CS Inst. Technol. Drug Anal., Med. Acad., Gdansk, Pol.

SO Pol. J. Pharmacol. Pharm. (1974), 26(6), 639-46

CODEN: PJPPAA

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Cyanomethylbenzimidazoles I (R,R<sub>1</sub> = H, Me) were prepd. by treating the o-phenylenediamines with NCCH<sub>2</sub>CO<sub>2</sub>Et. I were converted to their amidoximes and thioamides. II (R<sub>2</sub> = H, Me, Et, Pr, Ph) were prepd. by treating the benzimidazoles with ClCH<sub>2</sub>CN and were hydrolyzed to their amides and acids.

IT **54980-92-6P 54980-94-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

L65 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2000 ACS

AN 1973:111212 HCAPLUS

DN 78:111212

TI Acrylamidization of benzimidazoles

AU Efros, A. M.; Usaevich, O. N.

CS USSR  
SO Zap. Leningrad. Sel'sk. Khoz. Inst. (1972), No. 180, 49-51  
From: Ref. Zh., Khim. 1972, Abstr. No. 16Zh374  
DT Journal  
LA Russian  
GI For diagram(s), see printed CA Issue.  
AB CH<sub>2</sub>:CHCONH<sub>2</sub> was added portionwise to benzimidazole and Et<sub>3</sub>(PhCH<sub>2</sub>)NOH in pyridine and the mixt. stirred 4 hr to give I (R = R<sub>1</sub> = H), which heated 14 hr with aq. Ba(OH)<sub>2</sub> gave II (R = H). Similarly, 5(6)-nitrobenzimidazole (5-6 hr at 45-50.degree.) gave I (R = H; R<sub>1</sub> = 5-NO<sub>2</sub>) and I (R = H, R<sub>1</sub> = 6-NO<sub>2</sub>). Similarly, 2-methylbenzimidazole gave (8 hr heating) 65% I (R = Me, R<sub>1</sub> = H), which as above gave II (R = Me). Also prepd. was I [R = Me, R<sub>1</sub> = 5(6)-NO<sub>2</sub>].  
IT **22492-17-7P 40508-01-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

L65 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2000 ACS  
AN 1969:96715 HCAPLUS  
DN 70:96715  
TI Acylation of nitrogen heterocycles under the conditions of the Schotten-Baumann reaction. I. Benzimidazoles  
AU Ben-Ishai, Dov; Babad, E.; Bernstein, Z.  
CS Technion-Israel Inst. Technol., Haifa, India  
SO Israel J. Chem. (1968), 6(5), 551-67  
CODEN: ISJCAT  
DT Journal  
LA English  
AB 1-(R-Substituted)-2-(R<sub>1</sub>-substituted)benzimidazoles (I) are acylated to give phenylenediamines o-RN(COR<sub>1</sub>)-C<sub>6</sub>H<sub>4</sub>NHCOR<sub>2</sub> (II); 1-(R-substituted)-2-(R<sub>1</sub>-substituted)-3-(R<sub>2</sub>-substituted)-2-hydroxybenzimidazolines (III) and 1-(R-substituted)-3-(R<sub>1</sub>-substituted)-2-benzimidazolones (IV) are also prepd. Thus, 0.005 mole I (R<sub>1</sub> = H) are treated with 0.0075 mole ClCO<sub>2</sub>CH<sub>2</sub>Ph in EtOAc in the presence of N NaHCO<sub>3</sub> to give N-phenethyl-N'-formyl-N'-carbobenzoxy-o-phenylenediamine, m. 85-6.degree., and the following II (R<sub>1</sub> = H, R<sub>2</sub> = OCH<sub>2</sub>Ph) (R and m.p. given): PhCH<sub>2</sub>, 108-9.degree.; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 107-8.degree.; Ph, 130-1.degree.; CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, 178-9.degree.; CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, 103-4.degree.; CH<sub>2</sub>CO<sub>2</sub>CH<sub>2</sub>Ph, 97-9.degree.; CH<sub>2</sub>CONH<sub>2</sub>, 181-2.degree.; CH<sub>2</sub>CO<sub>2</sub>H 144-5.degree.; CH<sub>2</sub>CH<sub>2</sub>O<sub>2</sub>Bz, 88-90.degree.; CH<sub>2</sub>CH<sub>2</sub>SCH<sub>2</sub>Ph, -; and p-O<sub>2</sub>N-C<sub>6</sub>H<sub>4</sub>, 158-9.degree.. Similarly prepd. are the following II (R = PhCH<sub>2</sub>, R<sub>1</sub> = H) (R<sub>2</sub> and m.p. given): OMe, 117-18.degree.; OEt, 132-3.degree.; and O<sup>i</sup>Bu-iso, 108-9.degree.; the following II (R<sub>1</sub> = H, R<sub>2</sub> = Ph) (R and m.p. given): PhCH<sub>2</sub>CH<sub>2</sub>, 164-5.degree.; PhCH<sub>2</sub>, 118-19.degree. p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 153-4.degree.; Ph, 131-2.degree.; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 106-8.degree.; BzOCH<sub>2</sub>CH<sub>2</sub>, 146-7.degree.; EtO<sub>2</sub>CCH<sub>2</sub>, 107-8.degree.; and H<sub>2</sub>NCOCH<sub>2</sub>, 174-5.degree.; the following II (R = PhCH<sub>2</sub>CH<sub>2</sub>, R<sub>1</sub> = H) (R<sub>2</sub> and m.p. given): p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 134-5.degree., o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 159-60.degree.; p-MeOC<sub>6</sub>H<sub>4</sub>, 80-3.degree.; o-MeOC<sub>6</sub>H<sub>4</sub>, 118-19.degree.; and o-tolyl, 88-9.degree.; the following II (R = PhCH<sub>2</sub>, R<sub>1</sub> = H) (R<sub>2</sub> and m.p. given): p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 11-13.degree.; o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 62-3.degree.; p-MeOC<sub>6</sub>H<sub>4</sub>, 105-6.degree.; o-MeOC<sub>6</sub>H<sub>4</sub>, 104.degree.; and o-tolyl, 119-20.degree.; the following II (R = EtO<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>, R<sub>1</sub> = H) (R<sub>2</sub> and m.p. given): p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 116-18.degree.; p-MeOC<sub>6</sub>H<sub>4</sub>, -; o-MeOC<sub>6</sub>H<sub>4</sub>, 84-5.degree.; and o-tolyl, -; the following II (R = H<sub>2</sub>NCOCH<sub>2</sub>CH<sub>2</sub>, R<sub>1</sub> = H) (R<sub>2</sub> and m.p. given): p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 156-7.degree.; o-MeOC<sub>6</sub>H<sub>4</sub>, 170-1.degree.; and o-tolyl, 114-16.degree.; the following II (R = PhCH<sub>2</sub>, R<sub>2</sub> = PhCH<sub>2</sub>O) (R<sub>1</sub> and m.p. given): Me, 127-9.degree.; PhCH<sub>2</sub>, 101-2.degree.; and Ph, 144-6.degree.; and II (R = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H, R<sub>2</sub> = Bz) (m. 107-8.degree.), I (R = H, R<sub>1</sub> = PhCH<sub>2</sub>) gives II (R = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = Me, R<sub>2</sub> = PhCH<sub>2</sub>O) (m. 121-2.degree.). I (R = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H) (m. 69-70.degree.) is treated with ClCO<sub>2</sub>CH<sub>2</sub>Ph to give III (R = R<sub>2</sub> = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H), m. 114-16.degree.; similarly prepd. is III (R = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H, R<sub>2</sub> = Bz) (m. 107-8.degree.). I (R = H, R<sub>1</sub> = PhCH<sub>2</sub>) gives III (R = R<sub>2</sub> = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = PhCH<sub>2</sub>) (m. 91-3.degree.). III (R = R<sub>2</sub> = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H) is treated with NaOH to give 2-benzimidazolone and II (R = H, R<sub>1</sub> = R<sub>2</sub> = PhCH<sub>2</sub>O). Also prepd. are (m.p. given): IV (R = PhCH<sub>2</sub>O<sub>2</sub>C, R<sub>1</sub> = H), 175-6.degree.; II

(R = R1 = H, R2 = Ph), 154-5.degree.; II (R = H, R1 = PhCH2O, R2 = Ph), 112-13.degree.; III (R = R2 = PhCH2O2C, R1 = PhCH2), 91-3.degree.; IV (R = PhCH2O2C, R1 = PhCH2CO), 131-2.degree.; IV (R = Ac, R1 = PhCH2O2C), 140-1.degree.; IV (R = PhCH2O2C, R1 = H), 175-6.degree.; and IV (R = Ac, R1 = H), 205-7.degree.; the following I (R1 = H) (R and m.p. given); PhCH2CH2, 77-8.degree.; p-O2NC6H4CH2, 102.degree.; p-O2NC6H4, 186-7.degree.; EtO2CCH2CH2, -; H2NCOCH2CH2, 181-3.degree.; HO2CCH2CH2, 151-2.degree.; HOCH2CH2, 107-8.degree.; BzOCH2CH2, 114-15.degree.; ClCH2CH2, 86-7.degree.; and PhCH2SCH2CH2, 101-2.degree.. Also prepd. were (m.p. given): I (R = PhCH2, R1 = Me), 68-9.degree.; I (R = R1 = Ph-CH2), 143-4.degree..

IT **22492-17-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

=> fil uspat

FILE 'USPATFULL' ENTERED AT 10:45:33 ON 31 AUG 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Aug 2000 (20000829/PD)  
FILE LAST UPDATED: 29 Aug 2000 (20000829/ED)  
HIGHEST PATENT NUMBER: US6112326  
CA INDEXING IS CURRENT THROUGH 29 Aug 2000 (20000829/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Aug 2000 (20000829/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jul 2000  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jul 2000

>>> Page images are available for patents from 1/1/1997. Current <<<  
>>> week patent text is typically loaded by Thursday morning and <<<  
>>> page images are available for display by the end of the day. <<<  
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
>>> is included in file records. A thesaurus is available for the <<<  
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
>>> fields. This thesaurus includes catchword terms from the <<<  
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
>>> available for the WIPO International Patent Classification <<<  
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
>>> the /IC5 and /IC fields include the corresponding catchword <<<  
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d l66 bib abs hitrn tot

L66 ANSWER 1 OF 3 USPATFULL

AN 95:3866 USPATFULL

TI Arylethylamine compounds

IN Lesieur, Daniel, Gondecourt, France

Yous, Said, Lille, France

Depreux, Patrick, Armentieres, France

Andrieux, Jean, Antony, France

Adam, Gerard, Le Mesnil Le Roi, France

Caignard, Daniel H., Paris, France

Guardiola, Beatrice, Neuilly Sur Seine, France

PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)

PI US 5380750 19950110

AI US 1993-93769 19930719 (8)

RLI Division of Ser. No. US 1992-931574, filed on 12 Aug 1992, now patented,  
Pat. No. US 5276051, issued on 4 Jan 1994

PRAI FR 1991-10261 19910813  
DT Utility  
EXNAM Primary Examiner: Brust, Joseph Paul; Assistant Examiner: Gabilan, Mary Susan H.  
LREP Hueschen, Gordon W.  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 910

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a compound selected from those of formula (I):  
##STR1## in which Ar', R.sub.1 and R.sub.2 are as defined in the  
specification, an optical isomer,

and an addition salt thereof with a pharmaceutically-acceptable acid or  
base.

Medicinal product which is useful in treating or in preventing a  
disorder of the melatoninergetic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **147621-92-9P**  
(prepn. and pharmaceutical applications of)

L66 ANSWER 2 OF 3 USPATFULL  
AN 94:37963 USPATFULL  
TI Benzofuran ethylamine compounds  
IN Lesieur, Daniel, Gondecourt, France  
Yous, Said, Lille, France  
Depreux, Patrick, Armentieres, France  
Andrieux, Jean, Antony, France  
Adam, Gerard, Le Mesnil Le Roi, France  
Caignard, Daniel H., Paris, France  
Guardiola, Beatrice, Neuilly Sur Seine, France  
PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)  
PI US 5308866 19940503  
AI US 1993-93279 19930719 (8)  
RLI Division of Ser. No. US 1992-931574, filed on 12 Aug 1992  
PRAI FR 1991-10261 19910813  
DT Utility  
EXNAM Primary Examiner: Brust, Joseph Paul; Assistant Examiner: Gabilan, Mary Susan H.  
LREP Hueschen, Gordon W.  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a compound selected from those of formula (I):  
##STR1## in which Ar', R.sub.1 and R.sub.2 are as defined in the  
specification, an optical isomer,

and an addition salt thereof with a pharmaceutically-acceptable acid or  
base.

Medicinal product which is useful in treating or in preventing a  
disorder of the melatoninergetic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **147621-92-9P**  
(prepn. and pharmaceutical applications of)

L66 ANSWER 3 OF 3 USPATFULL  
AN 94:1444 USPATFULL  
TI Arylethylamine compounds  
IN Lesieur, Daniel, Gondecourt, France



Yous, Said, Lille, France  
Depreux, Patrick, Armentieres, France  
Andrieux, Jean, Antony, France  
Adam, Gerard, Le Mesnil le Roi, France  
Caignard, Daniel H., Paris, France  
Guardiola, Beatrice, Neuilly sur Seine, France  
PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)  
PI US 5276051 19940104  
AI US 1992-931574 19920812 (7)  
PRAI FR 1991-10261 19910813  
DT Utility  
EXNAM Primary Examiner: Brust, Joseph Paul; Assistant Examiner: Gabilan, Mary Susan H.  
LREP Hueschen, Gordon W.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 774  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to a compound selected from those of formula (I):  
##STR1## in which Ar', R.sub.1 and R.sub.2 are as defined in the  
specification, an optical isomer,  
  
and an addition salt thereof with a pharmaceutically-acceptable acid or  
base.  
  
Medicinal product which is useful in treating or in preventing a  
disorder of the melatoninerbic system.  
  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
IT **147621-92-9P**  
(prepn. and pharmaceutical applications of)